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The ASK TEAMS approach: A systematic way to investigate 
couples with recurrent miscarriages 
 




Miscarriages are one of the commonest reasons that women in their reproductive 
years present to an Emergency Department, and they account for a large proportion 
of admissions, procedures, and morbidity of such patients. While a single miscarriage 
occurring in 15-20% of all clinically recognized pregnancies may be an isolated event 
for most women, recurrent pregnancy losses (RPL) account for 1-4% of all losses 
and are a separate clinical entity. Most recurrent miscarriage clinics now divide 
miscarriages according to gestational age, with those less than or equal to ten weeks 
termed embryonic losses, and those from ten to twenty weeks as fetal losses, 
instead of the original first or second trimester losses. 
It is a frustrating situation both for the Couples suffering the losses, and for their 
Physicians, given the lack of good quality evidence regarding the management of 
these couples. 
Recurrent pregnancy loss is seldom due to a single pathogenic factor, and most have 
a multifactorial background, involving multiple genetic and environmental risk factors. 
In a dedicated recurrent miscarriage clinic, the aim was to develop an evidence-






A detailed history was obtained, and the diagnostic testing eventually led to the “ASK 
TEAMS” approach to identify potential issues that could lead to patient specific, safe 
and effective interventions. 
The “ASK TEAMS” approach is as follows: 
A Age: Patients were offered an Anti Müllerian Hormone test as part of the work 
up; 
S Structure: Patients were offered a luteal phase 3D ultrasound for assessment 
of the pelvis and uterus; 
K Karyotype: Miscarriage products were sent for karyotyping. Parental 
Karyotyping was restricted to those in whom a translocation had been 
detected in the products of conception; 
T Thrombophilia: Screening for hereditary thrombophilias was restricted to those 
with a strong personal or family history of venous thromboembolism; 
E Endocrine: All patients were offered thyroid function tests, a 75g oral glucose 
tolerance test (OGTT) including insulin levels; 
A Autoimmune: Antibody tests included thyroid peroxidase antibodies (TPO), 
anti-thyroid receptor antibodies (ATA), antinuclear antibody (ANA) titres. The 
antiphospholipid syndrome antibodies were also included; 
M Metabolic: OGTT and Insulin studies, and patients also had fasting circulating 
homocysteine concentration quantified; 
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S Specific: Vitamin D, B12 and folate studies were performed. Male partners 
were also tested for factors thought to contribute to sperm DNA damage, 
which may contribute to early miscarriages. 
 Results 
While many of the findings were consistent with those of recurrent miscarriage clinics 
world-wide, some novel observations were made: 
a) AMH levels were found to be significantly lower than in a normal population; 
b) Women with raised fasting or two-hour insulin levels had an increased risk of 
gestational diabetes in a subsequent pregnancy; 
c) Low vitamin D levels were significantly associated with hyperinsulinism in 
miscarriage patients. 
 Conclusions 
The ASK TEAMS approach to investigations in an RPL Clinic facilitates a consistent 
work-up. Tests are adjusted as evidence accumulates regarding miscarriage 










It always seems impossible until 
it’s done.  
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CHAPTER 1: Literature Review 
1.1 Introduction 
Recurrent Pregnancy Loss (RPL) is a life changing event for couples planning 
parenthood, and frequently a perplexing and challenging issue for their physicians. 
Despite the prevalence, research activity on recurrent miscarriages as measured by 
the the frequency of publications in relevant medical journals, or presentations at 
medical conferences, is extremely sparse, compared to research into assisted 
reproductive technology. There is also little or no consensus on the timing, 
gestational age or even the number of losses that comprise ‘recurrent’ losses. This 
vulnerable group of patients certainly comprise a significant proportion of patients 
who complain about the standard of care at an Institution, citing the lack of 
compassion for their situation, and the dearth of information about possible causes or 
interventions. Given the relatively minor medical impact of a miscarriage in 
comparison to major pregnancy complications and emergencies, it is obvious why 
such situations arise. However, if Institutions do not set up Early Pregnancy Units or 
Miscarriage Clinics, these patients are left with few explanations and minimal 
information, and may descend into depression and anxiety, or access some non-
evidence based, potentially harmful, interventions. 
1.2 Background 
Pregnancy losses are the most common complication of pregnancy, occurring in up 
to 50 - 75% of all couples who are planning parenthood. Many of these losses were 
previously unrecognized, and occured before or with the next period, or slightly later, 
at which time they would have been presumed to be just a late period (RCOG, 2003). 
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However, with the advent of increasingly sensitive home pregnancy tests, more of 
the previously named ‘biochemical pregnancies’ are being identified by patients, and 
then counted as losses. A pregnancy that is confirmed by serum or urine Beta-HCG 
(β-HCG) levels, including non-visualized pregnancy losses after 6 weeks, (post 
heavy bleeding but no confirmatory ultrasound), and treated pregnancies of unknown 
location, are included. Ectopic pregnancies, molar pregnancies and implantation 
failures are not included. However, miscarriages after ART treatments should be 
included (Kolte et al., 2015). These pregnancies are further divided into Recurrent 
Early Pregnancy Losses, (REPL) or Embryonic Losses, before ten weeks of 
gestation. Losses from 10 weeks until the unit viability definition, would be Fetal or 
Recurrent Late Pregnancy losses (Atik et al., 2018). 
Approximately 5% of couples planning a pregnancy will have two losses, and 
approximately 1% of couples will suffer three losses during their reproductive lives. 
As it has been estimated that the probability of three consecutive losses is about 
0.34%, this is unlikely to be due purely to random chance (RCOG, 2003). Of 
recognized losses, 15 – 20% are ectopic pregnancies or spontaneous miscarriages 
that are diagnosed after clinical recognition of pregnancy. Unfortunately, the risk for a 
subsequent pregnancy loss increases with each successive loss. After one loss, the 
couple has approximately the normal population baseline risk of having another one, 
which is  approximately 15% (Nybo Andersen et al., 2000). However, should they 
suffer two losses the subsequent risk increases to approximately 25%, depending on 
the combined age of the couple. Several studies have estimated that the risk of 
pregnancy loss after three successive losses is 30 – 45%, and up to 75% if the 
combined age of both partners is greater than 75 years (Petrozza et al., 2004; de la 
Rochebochard et al., 2003). 
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Recurrent Pregnancy Loss (RPL) is an independent risk factor for other adverse 
pregnancy outcomes including preterm labour, preeclampsia and gestational 
diabetes (Yang et al., 2006). Therefore, investigation of these patients could identify 
novel risk factors for such outcomes, and possibly inform early opportunities for 
intervention and treatment. Current trends in research in fetal medicine focus on the 
prediction (at 12 weeks of gestation) of patients at risk of adverse outcomes such as, 
preeclampsia, abruptio placenta, intrauterine growth restriction and stillbirth, but this 
is too late for women with embryonic loss. Given that first trimester placental 
development is implicated in a wide range of pregnancy complications (Roberts, 
2010), identification of women at risk at 12 weeks’ may be too late to reverse the 
aberrant placental developmental trajectory. By investigating the recurrent 
miscarriage patients following their loss, blood and other tests can be performed, 
potentially guiding substantial improvements to lifestyle, medication and/or 
supplementation. Identification of these patients prior to pregnancy would be far more 
cost effective than finding and treating them in the first trimester. Test results would 
presumably reflect the internal environment that may contribute to the losses, before 
women have taken steps to improve them, as the latter can confound future 
investigations and interventions. The prevailing belief has been that about 50% of 
recurrent pregnancy losses may have a risk factor detected (Bashiri et al., 2016, Li et 
al., 2002), which may or may not be the actual cause. Very few cases of RPL are 
caused by a single factor, the majority being an interaction between multiple genetic 
and environmental risk factors (Bashiri et al., 2016). However, in 2018 Popescu et 
al., investigated the addition of a 24-chromosome microarray of miscarriage tissue, 
along with routine investigations offered at their institution, at the time of a second or 
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later loss, and detected a definate or probable cause in 95% of the patients 
investigated (Popescu et al., 2018). 
The heterogeneity and complexity make RPL difficult to research. To identify causal 
factors and test therapeutic interventions, large patient and control populations in 
multi-centre trials are needed to obtain level 1 evidence. As RPL is a far rarer 
condition than infertility, and given that there are very few dedicated RPL clinics, 
current evidence is limited to small trials. 
Christiansen et al., (2014) suggested that there were two possible scenarios. 
Chromosomal errors resulting in losses with the rate of such losses being explained 
by chance and increased risk. The other, that maternal environmental issues such as 
endocrine, thrombophilic, structural or immunological abnormalities, could increase 
the losses of euploid conceptions, which, if detected, could be treatable. Such 
treatments/interventions would need to be evaluated in randomized controlled trials 
(Christiansen et al., 2014). 
Identifying this complex group should be the role of recurrent miscarriage clinics, 
leading to evidence-based interventions. Genetic factors detected in families with 
RPL predisposition, may also increase risk for adverse pregnancy outcomes such as 
intrauterine growth restriction, preeclampsia and perinatal complications 
(Christiansen et al., 2014). A Maternal predisposition to endothelial cell inflammatory 
injury may also be part of the problem, as a factor that negatively affects placental 
growth, thus increasing the association between adverse obstetric and neonatal 





The pathogenesis of miscarriage involves a complex interaction of multiple factors, 
including environmental and life style factors and genetic factors as well (Zetterberg 
et al., 2004). There is also controversy regarding the number of miscarriages that 
constitute ‘recurrent’ pregnancy loss, and thus confusion as to when to classify a 
patient as ‘recurrent’ and in need of a full RPL evaluation. The Royal College of 
Obstetricians and Gynaecologists (RCOG) Green-top guidelines state that “recurrent 
miscarriage, defined as the loss of three or more consecutive pregnancies, affects 
1% of couples trying to conceive” (RCOG 2011). The American Society for 
Reproductive Medicine (ASRM) in 2012, defined RPL as “a distinct disorder defined 
by two or more failed clinical pregnancies” (ACOG 2008). However, Kolte et al., 
(2014) showed that even non-visualized pregnancy losses are prognostically 
important in unexplained recurrent miscarriages. Specifically, each additional non-
visualized loss conferred a similar risk for not achieving a live birth as the risks of 
each clinical miscarriage.. Jaslow et al., (2010), showed that the findings in recurrent 
miscarriage patients after two, three or more losses did not differ significantly among 
the women with these losses and suggested that investigations should be performed 
following two or more consecutive losses. The latest European Society of Human 
Reproduction (ESHRE) Guidelines on RPL has accepted ‘recurrent pregnancy loss’ 
as two or more spontaneous losses before the fetus reaches viability. This would 
therefore include all pregnancies from conception until 24 weeks (Atik et al., 2018). 
However, many countries, including Australia, do not include losses over 20 weeks, 
and such losses are subsequently included in the Perinatal Morbidity and Mortality 
statistics for each Institution. Such losses would then be investigated as extreme 
preterm labour and stillbirth, despite the non-viability status. Each Institution may also 
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have different cut-offs for determining viability and deciding when intervention may be 
offered (Bashiri et al., 2016). 
Consensus among clinicians working with RPL patients has not yet been achieved 
regarding the optimal work up, classification and interventions that should be offered. 
Clinicians working in the area should strive to consolidate existing knowledge, 
develop protocols and guidelines for management, and hopefully support 
Multicentered Randomized Controlled Trials, that could advance evidence-based 
treatment. 
The presumed causes are varied and often controversial, with more than one 
‘etiological factor’ being present. More than 50% of miscarriages are currently 
considered ‘unexplained’. The loss of aneuploid pregnancies is expected, and there 
is a good prognosis following these losses, with a lower risk of a repeated 
miscarriage. It is the loss of euploid pregnancies that are of most concern, especially 
as many studies have suggested that the recurrence risk increases with the number 
of previous losses (Christiansen et al., 2014; Jaslow et al., 2010). 
Prognosis should therefore be estimated by monitoring the number of live births per 
unit time after a diagnosis of recurrent miscarriages is determined (Jaslow et al., 
2010). In a Danish study using complete national birth registries, over a period of 22 
years, it was found that in women identified as ‘recurrent miscarriage patients’, 
66.7% had achieved a live birth after 5 years and 71.1% after 15 years (Jaslow et al., 
2010). Among women who had experienced 6 or more miscarriages, 50.2% had 
achieved a live birth after 5 years (Jaslow et al., 2010). 
Primary RPL is defined as pregnancy loss without any previous live births, and 
secondary RPL is when the couple has had at least one live birth, and experience 
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pregnancy losses as well. Controversy remains as to whether there are differences in 
findings between these two groups, regarding the live birth rates (Christiansen et al., 
2007; Bashiri et al., 2012). 
Defining the gestational age of RPL’s for the purposes of counselling and possible 
investigations is very important. Couples experiencing extremely early losses are 
more likely to have aneuploidy than those experiencing later losses in the second 
trimester. In the Second trimester losses are more likely to have structural 
abnormalities, cervical insufficiency and thrombophilias than first trimester losses, but 
no presumed etiology is restricted to a certain gestational age (Ohno et al., 1991; 
Drakely et al., 1998; Fritz et al., 2011; Bashiri et al., 2016). 
Every couple experiencing RPL should have access to a complete work up and 
possible evidence-based interventions. How each clinic defines RPL and determines 
their investigations depends on their population and the availability of the selected 
tests for presumed causes. 
The most common presumed ‘causes of’ or ‘associations with’ RPL’s are as follows: 
Genetic, structural, autoimmune, thrombophilic, endocrine, parental age, metabolic 
and lifestyle (Bashiri et al., 2016).  
1.3.1 Age  
Maternal age is one of the commonest independent risk factors associated with 
pregnancy loss, and the risk of loss increases with advancing maternal age. Nybo 
Andersen et al., (2000) showed that the risk of miscarriage at age 20-24 years was 
approximately 8.9%, increasing to 74.4% in women aged 45 years or more. The 
ESHRE guidelines suggest that women ought to be informed that the risk of 
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pregnancy loss is lowest in women aged 20-35 years, and should have a discussion 
regarding the age of the couple, and the fact that the risk of pregnancy loss increases 
significantly after the age of 40 years (Atik et al., 2018). 
The term that is used to describe a woman’s reproductive potential, as it relates to 
the quality of her oocytes and her own individual follicular depletion, is ovarian 
reserve. Serum Anti-Müllerian Hormone (AMH) levels are an ideal marker of a 
woman’s ovarian reserve, as AMH is highly correlated with the number of antral 
follicles remaining. (Visser et al., 2006; Barad et al., 2009). AMH is a member of the 
transforming growth factor β family of growth and differentiation factors. AMH has an 
inhibitory effect on primordial follicle recruitment in the ovary, as well as on the 
responsiveness of the growing follicles to follicle stimulating hormone (FSH) (Barad 
et al., 2009). 
The ovary-specific expression pattern in granulosa cells of the growing non-selected 
follicles thus makes AMH an excellent marker for the size of the remaining ovarian 
follicle pool. The size of this  follicle pool is established very early intrauterine life. 
Germ cells populate the ovary and become surrounded by somatic cells, forming the 
so-called primordial follicles (Gruitjers et al., 2003). At birth, about one million oocytes 
are present. This number decreases pre-pubertally, resulting in a primordial follicle 
pool of 300 000 to 500 000 follicles at menarche (Gruitjers et al., 2003). Throughout a 
woman’s reproductive life, follicles leave the primordial follicle pool, and enter the 
growing antral follicle pool. Most of these growing follicles will be lost as a result of 
atresia, unless they are rescued by FSH (Baird et al., 2005). This rescue begins after 
puberty when the pituitary-gonadal endocrine axis has been activated. Only one 
follicle is selected to become the dominant follicle each menstrual cycle, ovulating 
under the influence of luteinizing hormone (LH) (McGee et al., 2005). This process 
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continues until the primordial pool is exhausted, resulting in menopause (Seifer and 
Naftolin, 1998). Fertility declines in the years preceding menopause, and the 
menstrual cycle becomes irregular, ultimately ceasing. There is significant individual 
variation in the age of menopause and, subsequently, also in the age of ‘subfertility’ 
(te Velde et al., 1998). Chronological age is thus a poor indicator of individual 
reproductive ageing and also of actual ovarian reserve (Faddy et al., 1998).  
Traditionally the ‘perimenopause’ was described as the time when ovarian function 
began to decline to the extent that clinical symptoms such as irregular menstruation 
started (Faddy et al., 1992). In recent years, assisted reproductive technology (ART) 
has given us a better understanding of the events that happen before the menopause 
(Dolleman et al., 2013). A significant decline in ovarian function begins much earlier 
than previously thought, most likely in the mid-thirties, (Volarcik et al., 1998) and 
possibly earlier in some women (Faddy et al., 1998). As a result of compromised 
endocrine, paracrine and autocrine signals due to the effects of ageing, there is 
altered communication between granulosa cells and the oocytes, which results in 
abnormal nuclear and cytoplasmic maturation within the oocyte. An accelerated loss 
of follicles then occurs, as well as qualitative changes in those remaining (Nikolau et 
al., 2002), (Bopp et al.,1998). The clinical result is an increase in the incidence of 
miscarriage and a decrease in fertility rates, both spontaneous conceptions and with 
ART. This frequently occurs without obvious clinical symptoms of endocrine 
deficiency, during the peri-menopausal period (Baird et al., 2005). 
Lyttle Schumaker et al., (2018) showed a marked increase in miscarriages in 
spontaneously conceived pregnancies of women with markedly decreased AMH 
levels. Their rate was twice that of women with normal levels, suggesting that AMH 




1.3.2 Structural and Pelvic abnormalities 
Congenital uterine abnormalities (CUA’s) have been thought to be a cause of 
pregnancy loss and adverse pregnancy outcomes (Christiansen et al., 2005). The 
reported prevalence of these abnormalities in women suffering recurrent pregnancy 
loss varies from 6 to 38% (Salim et al., 2003). CUA’s are thought to result from 
abnormal formation, fusion or resorption of the Müllerian ducts during fetal life 
(Jaslow et al., 2013). The prevalence of major CUA’s is thought to be at least 3-fold 
higher in women with a history of recurrent miscarriages in both embryonic 
(gestational age of <10 weeks from the last menstrual period) and fetal (gestational 
age of >10 weeks) loss, compared with the low risk population. Therefore, CUA’s 
may indeed be responsible for pregnancy loss in a significant proportion of women 
with recurrent miscarriages (Saravelos et al., 2005). 
Polycystic ovarian syndrome is a complex endocrine disorder characterized by 
anovulation and oligomenorrhoea, infertility, hyperandrogenism, and metabolic 
dysfunction (Trikudanathan et al., 2015). Polycystic ovaries may be detected on 3D 
ultrasound, as large volume ovaries containing greater than 25 peripherally 
distributed follicles, each measuring from 2 to 9mm in diameter. However, the 
detection of ‘Polycystic Ovaries’ does not establish a diagnosis of the Polycystic 
Ovarian Syndrome (PCOS), unless other features are present such as 
hyperandrogenism and chronic anovulation (Zhu et al., 2016). 
One study suggested that the prevalence of fibroids in women experiencing recurrent 
pregnancy losses was about 8.2% while that of the infertile population was 1 - 2.4% 
(Saravelos et al., 2011). Prevalence in the general population is thought to be from 3 
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-10%, however, it is difficult to estimate (Laughlin et al., 2009). Furthermore, fibroids 
are thought to be associated with mid-trimester losses amongst women with 
recurrent miscarriages (Saravelos et al., 2007). Pregnancy loss in women with 
submucosal fibroids is thought to be primarily due to decreased implantation rates. 
Resection of fibroids that distort the uterine cavity can eliminate the mid-trimester 
losses and result in a doubling of the live birth rate (Saravelos et al., 2007). In their 
group, the live birth rate increased from 23.3 to 52.0% (P<0.05) post myomectomy. 
Adenomyosis is a non-neoplastic condition, affecting many women, characterized by 
a benign invasion of the myometrium by ectopic endometrium, that is accompanied 
by hyperplasia of the adjacent smooth muscle (Martines-Conejero et al., 2011). Such 
invasion may be detected during a 3D ultrasound but there are insufficient studies 
available to be able to assign causation in relation to RPL. Endometriomas and 
endometriosis may be detected by 3D ultrasound. There is conflicting evidence 
regarding surgical removal of endometriomas, as such removal could damage the 
ovarian reserve, and compromise future fertility (Ahmadi et al., 2014). 
Asherman’s syndrome is described as the presence of intrauterine adhesions 
composed of fibrotic tissue and is a pathological condition associated with pregnancy 
loss. It is thought to arise following trauma to the basal layer of the endometrium, 
usually following a curettage, infection or inflammation, with a high level of 
recurrence, even after treatment (Ahmadi et al., 2014).  
 
1.3.3 Karyotype/Chromosomal 
Carp et al., (2001) noted, in a series of 167 cases, chromosomal abnormalities in 36 
(21.6%) of them, the commonest of which was trisomy, found in 24 (66.6%) of the 36 
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cases; 5 out of the 24 were trisomy 21, which was the commonest aberration, 
followed by trisomies 16 and 18, triploidy, monosomy X, and unbalanced 
translocations. Warburton et al., (1987) reported on 273 women who had two losses 
karyotyped and concluded there is no increased risk of another trisomy after a 
previous trisomic miscarriage, resulting in a very favourable prognosis for these 
women in subsequent pregnancies (Warburton et al., 1987).  
It is thought that 33% of all malformed fetuses approximately and 66% of malformed 
embryos have underlying chromosomal abnormalities. 3% of cytogenetically 
abnormal concepti also have structural rearrangements. In the familial translocations, 
66% are maternally derived and the remainder are of paternal origin. However, 
approximately 50% of all unbalanced translocations arise de novo during 
gametogenesis (Jacobs et al., 2013). Balanced parental rearrangements are found in 
3-6% of RPL’s and the most commonly encountered parental rearrangements 
include balanced translocations and inversions. The risk of future pregnancy losses 
in these cases is influenced by both the size and the genetic makeup of these 
rearranged chromosomal segments (Jacobs et al., 2013).  
While routine karyotyping of the couple was previously recommended, this has 
changed in recent years, particularly after it was shown by Franssen et al., (2006) 
that couples with at least two previous miscarriages who carried translocations or 
inversions, had the same chance of having a healthy child as non-carrier couples 
with at least two miscarriages, 83% and 84%, respectively. More importantly, these 
couples also had a low chance (0.8%) of carrying pregnancies with an unbalanced 
karyotype beyond the end of the first trimester (Warburton et al., 1987). Detection of 
an unbalanced translocation in the fetus or embryo should be followed by parental 
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studies. The latest ESHRE guidelines also suggest that parental studies should only 
be offered after a translocation is detected in the previous loss (Atik et al., 2018). 
Genome damage may be associated with adverse pregnancy outcomes, including 
recurrent miscarriages. Individual diets as a key factor in determining genomic 
stability is more relevant than previously thought, because it is now known that diet 
impacts on all relevant pathways, i.e. exposure to dietary carcinogens, 
activation/detoxification of carcinogens, DNA repair, DNA synthesis and apoptosis 
(Fenech et al., 2001). 
In 2018 Popescu et al., included a 24-chromosome microarray analysis on the 
products of miscarriages, as well as the recommended American Society for 
Reproductive Medicine (ASRM) standard work up, to establish if this would explain 
most losses. They discovered that a definite or probable cause was then identified in 




In the 1980’s, it was suggested that antiphospholipid antibodies (aPL’s) could have a 
causal association with recurrent miscarriages, following the detection of placental 
clots in patients with positive serum aPL’s and pregnancy loss (Kutteh et al.1996). In 
the 1990’s it was noted that treatment of these patients with aspirin and Heparin 
increased the live birth rate (Kutteh et al., 1996). The assumption was that clotting 
issues were the most likely cause,and assumed that the inherited thrombophilia’s 
such as factor V Leiden, (FVL 1691→A) prothrombin gene mutation, (20210G PGM), 
methylene tetrahydrofolate reductase (MTHFR) deficiency and antithrombin III (ATIII) 
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deficiency, could also cause pregnancy losses due to their direct or indirect ability to 
induce hypercoagulable states. MTHFR polymorphisms are thought to be associated 
with clotting due to the association with mild to moderate homocystinaemia, which is 
an independent risk factor for arterial thrombosis (Kutteh et al., 1996). These 
thrombophilias induce a hypercoagulable state via indirect or direct augmentation of 
prothrombin to thrombin, its active clot-inducing form. It was thought that these 
thrombophilias may also cause other adverse pregnancy outcomes such as 
intrauterine growth restriction (IUGR), placental abruption, preeclampsia and stillbirth 
(Kist et al., 2008). Despite numerous studies, results are conflicting, and level one 
evidence is lacking. Most of this inconsistency is due to including the incorrect patient 
groups, i.e. including embryonic losses when evaluating the effects of, for instance 
factor V, instead of just fetal losses. Kist et al., (2008) showed a higher incidence of 
FVL in women with recurrent fetal loss in the 2nd and 3rd trimester than in the 1st. 
Given the absence of a functional intervillous space up to 9-10 weeks of gestation 
(embryonic losses) it is unlikely that placental thrombosis would be an issue at this 
early stage (Kist et al., 2008). 
Activated factor V is a clotting protein that acts in conjunction with activated factor X 
to directly convert prothrombin to thrombin. A single gene defect (F5c.1691G>A and 
p.Arg506Gin) results in a protein that is resistant to inactivation, increasing levels of 
factor V, increased thrombin and therefore an increased risk of venous 
thromboembolism (VTE) (Lockwood et al., 2011). The heterozygous form of this 
mutation is the commonest inherited thrombophilia in the general population. 
However, the prevalence is low and less than 0.3% of women will have a VTE in 
pregnancy (Lockwood et al., 2011). 
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Two reviews concluded that female carriers of FVL G1691A have an increased 
relative risk for RPL (odds ratio [OR] 1.52, 95% confidence interval [CI] 1.06-2.19 and 
OR 2.02., 95% CI 1.60-2.55) (Bradley et al., 2012; Roger et al., 2010). 
However, the maternal-fetal medicine (MFM) network also emphasized a very low 
absolute risk (4.2%) of actual pregnancy loss in the women who carry the FVL gene 
defect (Roger et al., 2010). Atik et al., (2018), in the ESHRE guidelines on recurrent 
miscarriage, suggest that screening should not be performed unless it is in the 
context of research or in women with additional risk factors for thrombophilia. It 
should also be noted that such losses would be fetal and not embryonic (Atik et al., 
2018). 
PGM G20210 substitution mutation (F2 c20210G>A) is the second most common 
inherited thrombophilia, and causes a decrease in thrombin, with a resulting increase 
in concentration of prothrombin in the plasma of carriers. VTE incidence is low in 
heterozygotes at an absolute risk of 0.5% while homozygotes have a risk of 2-3%. 
Although Bradley et al., (2012) suggested an increased risk of RPL in F2 c20210G>A 
carriers, the MFM network did not find any association (Silver et al., 2010). 
Given that FVL and PGM have a low prevalence in the general population, and that 
women with these variants can have a normal pregnancy, it is felt that they have a 
relatively small impact on the absolute risk of a pregnancy loss, and high-quality 
evidence is lacking. The balance of benefit versus harm regarding these treatments 
has not been studied in any major trials. Bradley et al., 2012, in a large meta-
analysis, suggested that evidence is moderate that anticoagulation of women with 
recurrent pregnancy loss and FVL/PGM variants could lead lead to harm (Bradley et 
al., 2012). Each RPL case should be evaluated separately and the history of each 
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patient with regard to documented gestational age of previous losses taken into 
account. Fetal losses after establishment of a placenta may require a different 
approach with regard to anticoagulation, compared to embryonic losses. 
The efficacy and safety of aspirin and heparin in women with a history of at least two 
unexplained miscarriages with or without inherited thrombophilia have a limited 
number of studies (De Jong et al., 2014). A Cochrane review found no beneficial 
effect of anticoagulants in studies at low risk of bias, and thus the review does not 
support the use of anticoagulants in women with unexplained recurrent miscarriage. 
Further randomized controlled trials are needed; at present there is no evidence of a 
beneficial effect (De Jong et al., 2014). 
1.3.4.1. MTHFR 
One-carbon metabolism during embryonic development has been studied 
predominantly with regard to the development of the nervous system in the fetus. 
Pregnant women who are folate deficient have a greatly increased risk of having 
babies with neural tube defects (NTD) and peri conceptional folic acid 
supplementation protects against this effect. The molecular events that result in NTD 
due to folate deficiency are unknown but may include dysfunctional methylation of 
crucial metabolites in the developing embryo and/or abnormalities in neural cell 
proliferation, differentiation and apoptosis, which may be due to DNA nucleotide 
misincorporation that resulting from folate deficiency in rapidly proliferating cells 
(Govindaiah et al., 2009). It is thus possible that these critical events also might lead 
to decreased fetal viability and possibly pregnancy loss as well. A population-based 
case control study showed an increased risk of early miscarriages in pregnant 
women with low plasma folate levels and/or Vitamin B12 deficiency during 
30 
 
pregnancy, that results in elevated homocysteine concentrations in the embryo and 
increases the incidence of NTD (Govindaiah et al., 2009; Van Der Put et al., 1997; 
Steen et al., 1998). Three other studies suggested a direct embryotoxic effect of 
homocysteine (Rosenquist et al., 1997; Greene et al., 2003; Zetterberg et al., 2004). 
Recently there has been more emphasis on the likely role of epigenetic processes 
and DNA methylation that occurs throughout gestation. B6/B12 deficiencies also 
affect DNA methylation (Kos et al., 2018). 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that exists in the 
cytoplasm of cells and irreversibly reduces 5,10-methylenetetrahydrofolate to 5-
methylenetetrahydrofolate (Zetterberg et al., 2004). This is used to convert 
homocysteine to methionine by the enzyme methionine synthase. MTHFR is involved 
in regulating the circulatory levels of homocysteine. Folic acid, vitamin B6 and B12 
are also important cofactors in this metabolic pathway. Two single nucleotide 
polymorphisms (SNPs) are currently investigated in the MTHFR genotype of couples 
with recurrent miscarriages, C677T and A1298T. The normal ‘wild type’ allele at 
position 677 is C and the normal wild type allele at position 1298 is A. If substitutions 
occur at these loci, the patient then becomes ‘heterozygous or homozygous’ for the 
common thermolabile polymorphism (Zetterberg et al., 2004). 
Mutations in the MTHFR gene causes the enzyme to be thermolabile with mild loss 
of activity. Homozygosity for this gene variant is present in at least 11% of the 
Caucasian population and can lead to hyperhomocysteinaemia when there is a 
coexisting nutritional folate deficiency. Deficiencies of Vitamin B12 (cobalamin) and 
folic acid can also result in elevated plasma homocysteine levels (Zetterberg et al., 
2004). As the fetus inherits two of these alleles from the Mother and two from the 
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Father, couples with 2 or more polymorphisms in total, have the chance of 
transmitting at least 2 of these alleles to the fetus. 
In women, hyperhomocysteinaemia is associated with increased risk of having a 
child with a neural tube defect or a fetal loss. (Kos et al. 2018). However, folic acid 
supplementation during pregnancy lowers homocysteine concentration and reduces 
the risk of these adverse pregnancy outcomes. The association of MTHFR gene 
mutation with RPL is controversial, with conflicting reports in the literature. Nelen et 
al., (2000), noted that hyperhomocysteinaemia was a risk factor for recurrent 
pregnancy loss. Other authors found that women carrying the mutant allele of the 
MTHFR C677T polymorphism had elevated serum levels of homocysteine and 
idiopathic recurrent miscarriage, in a Middle-European White population (Unfried et 
al., 2002; Couto et al., 2005). The presence of an anti-cardiolipin antibody together 
with the MTHFR C677T mutation, is associated with recurrent abortions (Kumar et 
al., 2003), while an increased risk of spontaneous abortions with maternal MTHFR 
C677T genotype has been demonstrated (Lissak et al., 1999). However other reports 
indicate that MTHFR C677T homozygosity is not associated with recurrent 
pregnancy loss (Foka et al., 2000; Holmes et al., 1999). 
The biochemical consequences of these polymorphisms can be modified by 
increasing folate and Vitamin B12 supplementation in women. Whether the 
supplementation should be routine ‘standard’ doses or increased doses needs to be 
investigated. The only evidence to date regarding ideal doses is with reference to 
decreasing homocysteine concentrations, in non-pregnant patients (Holmes et al., 
1999). Studies have demonstrated that daily doses of folic acid at 5-10 mg resulted in 
higher serum folate levels, lower total plasma homocysteine levels, and improved 
endothelial function (De Vecchi et al., 2003). However, ACOG and the MFM network 
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does not recommend screening women for the MTHFR mutation with either adverse 





1.3.4.2. Protein C and Protein S Deficiency. 
Congenital protein C or S deficiency is an inherited disorder that causes abnormal 
blood clotting. Heterozygous protein C deficiency occurs in approximately 1 in 300 
adults (Clouse et al., 1986). Protein S deficiency occurs in about 1 in 20,000 people 
(Clouse et al., 1986). 
ESHRE guidelines suggested that hereditary thrombophilia should not be screened 
for except unless patrt of research studies, or in women likely to have additional risk 
factors for thrombophilia, such as a personal history of thrombosis or a strong family 
history of thrombosis (Atik et al., 2018). It must be stressed, however, that they are 
referring to all recurrent pregnancy losses, and not just embryonic. 
1.3.4.3 Antiphospholipid syndrome 
The Antiphospholipid syndrome (APS) was recognized over three decades ago to 
have a causal association with recurrent pregnancy loss and in 1996, Kutteh et al., 
demonstrated that treatment of pregnant women with antiphospholipid antibodies 
(APL) syndrome with aspirin and heparin increased the live birth rate to 80% (Kutteh 
et al., 1996). 
Antiphospholipid antibodies are a heterogeneous group of autoantibodies, that are 
detected in the sera of patients with both autoimmune and various non-autoimmune 
diseases. However, they may also be detected in subjects with no overt underlying 
disease – the primary antiphospholipid syndrome. (PAPS) (Kutteh et al., 2006). High 
titres of APL are associated with arterial and venous thrombosis, recurrent fetal loss, 
and thrombocytopenia, (Leaf et al., 2017, Roubey et al 1996), as well as stillbirth, 
preterm birth, preeclampsia and intrauterine growth restriction (Branch et al., 1989, 
Ticani et al., 2002). 
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The clinically relevant APL include the Lupus anticoagulant – Kaolin clotting time, 
(KCT) Dilute Russell Viper Venom test (DRVVT), anti-β2 glycoprotein 1 antibodies 
and anticardiolipin antibodies. In the general population the prevalence is 1-7%, 
(Lockwood et al., 1989), while in patients with RPL it is found in up to 20% 
(Lockwood et al., 1989, Jaslow et al.,2010). 
 
Criteria for the classification of patients with definite APS (Sapporo 
criteria) developed in 1998, (Lockshin et al., 2000) provide a basis for including 
patients with the syndrome in research protocols rather than a guide to diagnosing 
the syndrome in individual patients. In order to fulfil these “Sapporo criteria”, patients 
must have had either vascular thrombosis or fetal loss and demonstrate evidence of 
APL either by the detection of anticardiolipin antibodies or a positive lupus 
anticoagulant. Furthermore, autoantibodies must be detected on at least 2 occasions, 
12 weeks apart, in order to distinguish persistent autoimmune antibody responses 
from transient responses caused by infection or drug exposures (Lockshin et al., 
2000).  Although these criteria suggested three or more pregnancy losses, evidence 
by van den Boogaard et al., (2013) has shown no difference in the sequence of 
pregnancies, the total number of pregnancy losses or even in maternal age, between 
women with RPL and APS and women with unexplained RPL. Therefore, it is now 
considered justifiable to test for APS in women attending a RPL clinic who have a 
history of two or more pregnancy losses, whether consecutive or not (Van der 
Boogaard et al., 2013; Atik et al., 2018; Miyakis et al., 2006). 
A diagnostic workup for APL’s should be considered in all patients with venous or 
arterial thrombosis and/or fetal/embryonic losses for which there is no alternative 
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explanation, especially if the losses are recurrent (Miyakis et al., 2006). Likewise, 
unexplained thrombocytopenia, haemolytic anaemia and prolongation of any 
phospholipid coagulation tests should lead to determination of APL status (Oshiro et 
al.,1996, Bouvier et al., 2014). 
Although the risk of pregnancy loss in women with APL was initially thought to be the 
greatest from the 10th week of gestation onward, (fetal period) (Lockshin et al., 1985. 
Lima et al., 1996), it is now known that APL are also associated with early pregnancy 
loss, due to placental damage, including inadequate trophoblast invasion, which is 
the most common histopathologic finding (Kutteh et al., 2014). There is also evidence 
that women with APL have an increased risk of adverse pregnancy outcomes such 
as giving birth to a premature infant because of pregnancy-associated hypertension 
and uteroplacental insufficiency (Kutteh et al., 2014). 
Tong et al., (2014) in a systematic review concluded that although the underlying 
mechanisms by which APL cause adverse pregnancy outcomes are unknown, they 
reiterated the effects on trophoblast invasion, including reducing trophoblast viability, 
syncytialization and invasion in vitro. There is some corroborating evidence of these 
effects in vivo (Sebire et al., 2002; Bose et al., 2006) which could contribute to 
impaired placental development and dysfunction in APL affected pregnancies. 
Several studies also reported that APL may affect the production of cytokines, 
hormones and other signalling molecules by trophoblasts in vitro (Van Horn et al., 
2004; Stone et al., 2006). There is also some evidence that APL may affect placental 
coagulation and complement activation. However, thrombosis and complement 
activation are not likely to be the main mechanisms for the problems experienced in 
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women with APL, particularly regarding embryonic losses (Sebire et al., 2002, Salafia 
and Cowchock 1991). 
Determining the presence of APL’s could allow therapeutic intervention, and 
hopefully, prevent not only miscarriages, but also the associated adverse later 
pregnancy outcomes (Kutteh et al., 2014). Indeed, the recent ESHRE guidelines 
have recommended screening for APS in women with recurrent pregnancy loss as it 
can allow treatment that may not only prevent pregnancy loss but also decrease 
subsequent pregnancy complications (Atik et al., 2018). 
1.3.5 Endocrine 
Thyroid disorders have been considered as one of the commonest 
causes/associations with RPL. Hypothyroidism is thought to be one of the most 
common endocrinopathies detected among young fertile women, and thyroid 
disorders have been found to be associated with several adverse pregnancy 
outcomes, such as infertility, early pregnancy loss, preeclampsia, preterm labour and 
delivery and stillbirths (Negro et al., 2011; Vissenberg et al., 2015). Thyroid 
antibodies are also associated with several adverse pregnancy outcomes such as 
recurrent pregnancy losses and preterm deliveries even in women who are 
apparently euthyroid (Negro et al., 2011). Thyroid antibodies have been associated 
with increased rates of preterm deliveries in pregnant cohorts, when compared with 
women who were thyroid antibody negative (Glinoer et al.,1994; Ghafoor et al., 
2006). However, this association is not consistently demonstrated in other pregnancy 
cohorts (Tierney et al., 2009; Stagnaro-Green et al., 2005). Another study found an 
increase in perinatal infant death among patients who were antibody positive 
(Mannisto et al., 2009). 
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The definition of ‘normal’ thyroid stimulating hormone (TSH) during pregnancy is 
controversial, with some evidence suggesting that women with levels below 2.5 
mlU/L had significantly fewer pregnancy losses than women with higher levels 
(Negro et al., 2010). Subclinical hypothyroidism (SCH) in pregnancy has recently 
been defined as a TSH level above the pregnancy-related reference range with a 
normal serum thyroxine concentration (Stagnaro-Green et al., 2011). The majority of 
SCH is caused by autoimmune thyroiditis but may be due to iodine deficiency in 
some populations. (Lazarus et al., 2014; Bernadi et al., 2013). 
1.3.6 Autoimmune 
Women with autoimmune diseases such as systemic lupus erythematosus (SLE), 
have a higher risk of embryonic and fetal losses than women without such 
autoimmunity. (Christiansen et al., 2008). Some patients may have the Lupus 
anticoagulants (Kaolin clotting time KCT, or the dilute russell viper venom test 
DRVVT) positivity, concomitantly, and these are known to be associated with RPL. 
Antinuclear antibodies (ANA) have been studied in relation to losses, but the 
evidence is unconvincing regarding a direct link. It is more likely that they indicate an 
interruption in the women’s immune tolerance, and may be a marker of other 
autoimmune problems (Christiansen 1996). 
Antiphospholipid antibodies could be included in the autoimmune section, however, 
they have been discussed above for historical reasons, as many institutions still 
believe that they are associated with clotting. This is unlikely in the embryonic group 
due to the trophoblast structure. However, thrombophilias are most likely to be an 
issue in fetal losses. 
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Thyroid antibodies associated with thyroid autoimmunity is the commonest cause of 
thyroid dysfunction, and the presence of thyroglobulin autoantibodies (Tg-Abs) or 
thyroid peroxidase autoantibodies (TPO-antibodies) induces a chronic lymphocytic 
thyroiditis that can destroy the thyroid gland (Crawford et al., 2016). These antibodies 
are fairly common in women of reproductive age, and although they can lead to 
thyroid problems, most women with them are euthyroid (Bülow-Pedersen et al., 
2009). They are probably the manifestation of gene environment interactions. The 
genetic predisposition is most likely polygenic, involving several low-penetrance, low 
risk alleles. Environmental factors such as maternal low birth weight, selenium 
deficiency, iodine excess, and reproductive life span may also play a role in the 
development of antibodies (Prummel et al., 2004). Although the fetus does not make 
thyroxine until the second trimester, it does influence the maternal supply of thyroxine 
to itself. Thus, the conceptus, through the production of placental human chorionic 
gonadotrophin (hCG), indirectly increases the demand for thyroxine (T4), and also 
directly stimulates the maternal thyroid to produce T4 (Glinoer et al., 1990). In 
women with normal thyroid function, thyroxine equilibrium is maintained. Women with 
abnormal thyroid function need to increase their T4 levels in order to compensate for 
the demands of pregnancy and to maintain normal TSH levels (Alexander et al., 
2004). 
A meta-analysis of 22 studies showed a clear association between thyroid 
autoimmunity and miscarriage with a pooled odds ratio (OR) of 2.5 in eight case-
control studies and a pooled relative risk (RR) of 2.3 in 14 cohort studies (Chen et al., 
2011). Another meta-analysis of 31 studies evaluated linkage between anti-thyroid 
antibodies and miscarriage, with 28 studies showing a positive association 
(Thangaratinam et al., 2011). After dividing the meta-analysis into cohort and case-
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control studies, the data in the cohort showed an OR of 3.9 for miscarriage with the 
presence of thyroid autoantibodies. The OR of miscarriage for women with RPL with 
positive thyroid antibodies was 4.22. For case-control studies the OR for miscarriage 
was 1.8, and slightly higher in women with RPL (OR 1.86, p=0.008). (Thangaratinam 
et al., 2011). Clinical practice guidelines cosponsored by the American Association of 
Clinical Endocrinologists and the American Thyroid Association, state that anti-TPO 
measurement should be considered when evaluating patients with RPL, regardless 
of infertility (Garber et al., 2012). A recent systematic review and meta-analysis 
confirmed the benefits of levothyroxine (LT4) supplementation on both naturally 
conceived and ART pregnancies in women with SCH. Supplementation was 
associated with a decrease in both pregnancy loss and pre-term delivery (Rao et al., 
2019). 
The ESHRE guidelines suggest that thyroid screening (TSH and Thyroid peroxidase 
antibodies -TPO) is recommended in women with RPL, and that abnormal TSH and 
TPO-antibody levels should be followed up by thyroxine (T4) testing in these women. 






Women with uncontrolled pregestational diabetes, appear to have higher rates of 
pregnancy loss. Monitoring the haemoglobin A1c (HbA1c) levels is an excellent 
indicator of blood glucose control, and women with HbA1c levels higher than 8% 
have higher rates of pregnancy loss. Diabetic women who manage to control blood 
glucose levels within the normal range, have similar rates of pregnancy loss to 
women who are not diabetic (Mills et al., 1988). 
1.3.7.2 Hyperinsulinism  
Insulin resistance (hyperinsulinism) is a condition in which the sub-optimal efficacy of 
insulin in promoting the uptake and utilization of available glucose by tissues, organs 
and cells, is lower than in non-insulin resistant individuals. This often occurs in the 
context of completely normal glucose levels but glucose levels may be raised (Wang 
et al., 2011). 
Insulin resistance/Hyperinsulinism (IR/HI) has been thought to be associated with 
pregnancy loss, particularly in patients with the polycystic ovarian syndrome (PCOS). 
Wang et al., (2011), considered the fasting, one, two and three-hour insulin levels, of 
recurrent miscarriage patients in the first trimester of pregnancy. They found a 
significant difference in both the insulin and glucose levels at one, two and three 
hours of testing, even when they excluded patients with PCOS. They concluded that 
there is an increased incidence of insulin resistance in recurrent miscarriage patients, 
in the first trimester of pregnancy, and suggested that only testing for fasting insulin 
and glucose in recurrent miscarriage patients, would be inadequate to determine 
insulin resistance (Wang et al., 2011). Maryam et al., (2012) also found insulin 
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resistance in 24% of women with RPL, compared to only 8% of controls, in a case-
control study. 
The mechanism underlying the association between HI and the risk for miscarriage is 
unknown. A few possible mechanisms have been suggested by studies involving 
patients with PCOS. Jakubowicz et al., (2004) found that HI led to reduced serum 
concentrations of insulin-like growth factor binding protein-1 (IGFBP-1) and 
glycodelin in early pregnancy, which would be expected to increase the chance of 
miscarriages. 
Glycodelin is an immunomodulatory protein involved in implantation, and Glycodelin -
A is found in abundant levels in the decidua in early pregnancy (Lee et al., 2016). It 
plays an important role in placental development and feto-maternal defence. 
Abnormal levels are associated with unexplained infertility and recurrent pregnancy 
loss (Lee et al., 2016). Insulin can regulate the concentrations of glycodelin and 
IGFBP-1 negatively, increasing the risk of miscarriages. HI may also increase the 
level of plasminogen activator inhibitor-1 and induce villous thrombosis, thereby 
reducing placental perfusion and villous hypoplasia, resulting in miscarriage (Glueck 
et al., 2006). Another hypothesis is that HI may cause an uncontrolled diabetic-like 
state in the fetal environment resulting in increased first trimester loss (Glueck et al., 
2006). High insulin levels have been shown in vitro to increase the transport of 
glucose by first trimester cytotrophoblasts independent of glucose level (probably by 
upregulation of the GLUT1 glucose transporter system) (Glueck et al., 2006). 
A recent study by Vega et al., 2019, found that elevated insulin levels were directly 
toxic to cultured first trimester trophoblasts, resulting in apoptosis of these cultured 
cells, increased damage to their DNA, and decreased cell survival. These effects 
42 
 
were prevented by the addition of Metformin (Vega et al., 2019). Insulin is typically 
considered as an antiapoptotic and progrowth hormone, however, exposure of 
human primary trophoblast cells to insulin in the absence of raised glucose levels 
resulted in significant damage (Vega et al., 2019). Despite the above reports, the 
current ESHRE guidelines have suggested that assessing for PCOS, fasting insulin 
and fasting glucose is not recommended in women with RPL as a method of 
improving subsequent pregnancy prognosis. It needs to be emphasized that this 
statement is mainly based on insufficient evidence (Atik et al., 2018). 
1.3.8 Specific 
1.3.8.1 Immunological causes 
The feto-placental unit is equivalent to an allograft and is similar to a heart or kidney 
transplant (Van Kampen et al., 2001). The maternal immune system needs to adapt 
to the different paternal alloantigens present and such ‘immune recognition’ is 
essential for the survival of the pregnancy (Christiansen et al., 2008). Antipaternal 
human leukocyte antigen (HLA) antibodies have been observed in 10-30% of all 
normal pregnancies (Van Kampen et al., 2001; Lashley et al., 2013). Immunological 
biomarkers associated with RPL in the blood have been extensively researched as 
potential causes/associations regarding recurrent miscarriages. These include: 
natural killer (NK) cells in the blood or decidual tissue, cytokines in blood or decidua, 
and investigations of classical or nonclassical HLA polymorphisms in patients with 
RPL, as well as studies of HLA protein expression on trophoblast (Laird et al., 2011). 
HLA incompatibility was previously thought to be an important cause of RPL but a 
large case-control study did not support a link between RPL and anti-HLA antibody 
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formation, and thus discounted the diagnostic value of alloantibodies detected as part 
of an RPL work-up (Bartel et al., 2011). 
ESHRE guidelines have suggested that there is in inadequate research into an 
association between pregnancy outcomes and HLA polymorphisms in women 
suffering RPL, and that the investigation of HLA-DR or other classical HLA genes 
should only be undertaken in the context of research (Atik et al., 2018).  
Class II HLA in women with secondary RPL after the birth of a male baby (HLA-
DRB1*15:01 and HLA-DRQB1*05:01/05:2) has been used as part of a work -up in 
Scandinavian women, with secondary loss after the birth of a male and in a research 
context (Atik et al., 2018). However, HLA-C has also recently been shown to be 
associated with recurrent miscarriages (Meuleman et al., 2017). HLA-C is the only 
classical HLA-I antigen expressed on trophoblast. It has been shown that HLA-C 
incompatibility between couples is significantly associated with unexplained recurrent 
miscarriage (Meuleman et al., 2017). 
1.3.8.2 Anti-HY antibodies 
Anti-HY antibodies are those directed against male-specific minor histocompatibility 
(HY) antigens that are expressed on most or all nucleated cells from males, (Nielsen 
et al., 2010) and hence could be expected in pregnancies bearing a male fetus. The 
evidence for testing these antibodies is sparse so warrants further investigation. The 






1.3.8.3 Natural Killer Cells 
NK cells are part of the innate immune system and can recognize and react against 
target antigens, without prior sensitization (Christiansen et al., 2008). This reaction 
can result in the destruction of cells or the secretion of an array of cytokines 
(Christiansen et al., 2008). Decidua and endometrium have a unique composition of 
NK cells called uterine NK (uNK) cells, that are thought to play a key role in the 
establishment of successful pregnancy by facilitating immunologic adaptation of the 
semiallogenic developing embryo (Lachapelle et al., 1996). 
More than 90% of lymphocytes in the luteal phase endometrium or decidual tissue in 
early pregnancy are low cytotoxicity, high cytokine producing NK cells, which carry a 
high density of the CD56 surface marker (CD56bright) assessed by flow cytometry but 
are negative for the CD16 marker (Laird et al., 2011). In contrast, 90% of the NK cells 
in peripheral blood carry the CD56DIMCD16 markers, which are associated with high 
cytotoxicity and low cytokine production. Although many studies have suggested that 
the levels of CD56 cells in peripheral blood taken prior to pregnancy is significantly 
higher in RPL women than in controls, (King et al., 2010; Lee et al., 2013) other 
studies have not found this association (Emmer et al., 1999). Several studies 
investigated the impact of NK cytotoxicity on the subsequent pregnancy outcome in 
RPL patients. Aoki et al., (1995) reported that RPL patients with high peripheral blood 
NK cytotoxicity before pregnancy had a significantly higher rate of pregnancy loss 
(71%) in the next pregnancy, than patients with a lower NK cytotoxicity (20%). 
Yamada et al., (2003) found a significantly higher NK cytotoxicity in patients with a 
subsequent euploid miscarriage compared with those with a live birth while Morikawa 
et al. (2001) found a non-significant tendency for the same. In contrast, another study 
found no difference. (Liang et al. 2012). Katano et al. (2013), in a large prospective 
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study however, provided the strongest argument against a significant role for the 
quantification of NK cytotoxicity in RPL patients. In a logistic regression analysis 
adjusting for recognized risk factors for miscarriage, high NK cytotoxicity before 
pregnancy had no impact on subsequent pregnancy loss rate.  
The composition of endometrial lymphocytes fluctuates significantly during the 
menstrual cycle with a six to ten-fold increase in the late luteal phase in comparison 
to the follicular phase, and similarly in the peripheral blood samples and 
endometrium (Russell et al., 2013). Thus, it has been questioned whether the 
endometrial NK cell subsets can accurately reflect those in the peripheral blood.  
Templer and Sacks 2016, highlighted the complexity of this issue regarding NK cells 
and reproductive failure. While NK cell activity may not favour successful 
reproduction, such NK cell activity may provide alternative protection against 
disease. Hence, the presumed benefits of the use of potent immunosuppressive 
agents needs to be assessed aganst the potential harms of such agents (Templer 
and Sacks, 2016) 
The ESHRE guidelines have stated that there is insufficient evidence in women 
suffering RPL, to recommend testing of either peripheral blood NK cells or 
endometrial NK cells (Atik et al., 2018). 
   1.3.8.4. KIR and HLA-C 
Extravillous trophoblast (EVT) of fetal origin is responsible for the remodelling of the 
maternal spiral arteries via the destruction of the media, essential for normal 
placentation. Specific uterine natural killer cells (uNK) are present in the decidua 
during the placental formation and interact with the invading trophoblastic cells 
(Moffett et al., 2016). The EVT expresses high levels of HLA-C, of maternal and 
46 
 
paternal origin, that is recognized by uterine NK cells (uNK) killer immunoglobulin-like 
cell surface receptors (KIRs) (Alesandru et al., 2017). KIRs are a complex family that 
includes both activator an inhibitory receptors, and the activation profile is genetically 
determined in each individual.  In uNKs, KIRs are the most variable receptors and 
there is diversity in gene numbers between individuals and allelic diversity at 
individual KIR loci (Alesandru et al., 2017). KIRs bind to ligands on trophoblastic cells 
and dysfunction has been associated with reproductive failure (Díaz-Peῆa et al., 
2019). 
This leads to diverse levels of functionality for NK and T cells once they actively 
engage with specific HLA class 1 molecules (Díaz-Peῆa et al., 2019). Combinations 
of KIR and HLA genes are associated with pregnancy complications such as 
recurrent pregnancy loss and preeclampsia.  The maternal KIR genes and their fetal 
ligands are highly variable, so different KIR/HLA-C genetic combinations occur in 
each pregnancy. KIR genes can be inhibitory or activating, and inhibitory KIRs are 
found more often in women who suffer pre-eclampsia, recurrent miscarriages or 
significant fetal growth restriction (Moffett et al., 2016).  
Faridi et al., (2010) showed that KIR and HLA-C allorecognition patterns implicative 
of dominant activation of natural killer cells contributed to recurrent miscarriages in 
their cohort. Dambaeva et al., (2016) showed that RPL in women with the KIR2DS1 
genotype was associated with an increased HLA-C2 allelic frequency, and suggested 
that KIR and HLA-C genotyping could be useful for predicting immune related 
problems in women with RPL. Díaz-Peῆa et al., (2019) suggested that demographic 
genetic studies need to be performed to better understand the successful KIR/HLA-C 
allotype combinations of a succcessful pregnancy outcome (Díaz-Peῆa et al., 2019).  
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1.3.8.5 Vitamin D deficiency 
There is increasing, but not always consistent, evidence that a deficiency of Vitamin 
D increases the risk of many adverse pregnancy outcomes, including miscarriages, 
gestational diabetes, intrauterine growth restriction, and preeclampsia (Aghakjafari et 
al., 2013). Vitamin D is thought to affect placental implantation, angiogenesis, 
oxidative stress, immune function, glucose homeostasis and endothelial function 
(Wei et al., 2014). The biological activity of Vitamin D occurs via two pathways – a 
slow genomic response, and a rapid, non-genomic response (Mizwiki and Norman, 
2009). The target organs for the non-classical actions of vitamin D include the 
adaptive and innate immune systems, heart, cardiovascular system, the pancreatic-
β-cells, brain and reproductive system (Christakos et al., 2007). Vitamin D is 
associated with multiple tissue responses, including regulation of hormone secretion, 
modulation of immune responses, and a control of cellular proliferation and 
differentiation (Mizwiki et al., 2009). Vitamin D has been reported to inhibit the 
proliferation of T helper 1 (Th1) cells and limit their production of cytokines, such as 
interferon gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-
α) (Mizwiki et al., 2009). Conversely, vitamin D induces T helper 2 (Th2) cytokines, 
such as IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 (Adams et al., 2008). Vitamin D has 
also been thought to be a modifiable environmental factor for Th 1-mediated 
autoimmune diseases and may be important for susceptibility to and severity of the 
disease (Chen et al., 2007). It regulates B cell immunity by down-regulating the 
proliferation and differentiation of B lymphocytes and inhibits IgG production (Ota et 
al., 2014). Some investigators have shown that vitamin D influences local 
inflammatory responses and induces decidualization for successful pregnancy. It 
may thus be an immune modulator during implantation (Diaz et al., 2009; Barrera et 
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al., 2008). A dominant Th2 response is important to maintain maternal-fetal 
relationships for a successful pregnancy outcome. Vitamin D is thought to skew the T 
cell compartment from a Th1 to a Th 2 type (Ota et al., 2014). Women with low 
vitamin D levels have significantly increased odds for autoimmune abnormalities, a 
risk factor for reproductive failure (Ota et al., 2014). 
A meta-analysis revealed that maternal vitamin D deficiency is associated with 
increased risk of gestational diabetes during pregnancy (Lu et al. 2016). Several 
studies have shown that vitamin D is required for the normal insulin production and 
secretion by the pancreas (Zitterman et al., 2006, Pittas et al., 2012). Verburg et al. 
(2016), showed a seasonal variation for GDM in a population-based study. Several 
lifestyle and psychosocial factors could have been influential in the 
pathophysiological mechanisms of the development of GDM in this study. Several 
other factors such as ambient temperature, nutrient intake, physical activity and 
vitamin D levels could affect maternal physiology, and fetal and placental 
development at a cellular level and thus contribute to the development of GDM. High 
serum vitamin D at 15 +/- 1 weeks’ gestation has been shown to protect against the 
development of gestational diabetes (Wilson et al., 2018). 
Vitamin D has anti-inflammatory effects, and vitamin D sufficiency has beneficial 
effects on improving islet-cell functions, insulin release and decreasing insulin 
resistance (Wimalawansa et al., 2016). These are likely due to signaling actions of 
vitamin D receptors present on pancreatic β-cells (Wimalawansa et al., 2016). 
Interestingly one study showed that there is an increased prevalence of insulin 
resistance in women with a history of recurrent pregnancy loss, compared with 
matched controls (Craig et al., 2002). 
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1.3.8.6 Sperm DNA damage 
The male partner confers 50% of the genomic material to the conceptus, and 
contributes not only to placental development, but also to that of the embryo (Carlini 
et al., 2017). Therefore, genetic and epigenetic alterations of sperm may have 
significant consequences, contributing to early pregnancy loss. Minor DNA damage 
in spermatozoa as a result of endogenous or exogenous insults are repaired by pre-
and post-replication repair mechanisms but major damage cannot be repaired. This 
results in poor-quality sperm. Thus, the male partner may contribute to pregnancy 
loss, despite morphologically normal sperm, by harboring sperm with DNA damage. 
DNA damage causes alterations in sperm quality and function, sperm-oocyte 
interaction, implantation and early placental and embryonic development, resulting in 
pregnancy loss (Robinson et al., 2012; Aitken et al., 2016). Paternal factors, therfore, 
may including age, obesity, smoking and exposure to environmental contaminants 
(Aitken et al., 2016; Carlini et al., 2017). These factors involved in poor sperm quality 
cause oxidative stress, and are also associated with pregnancy problems such as 
small for gestational age babies and preeclampsia (McCowan et al., 2011; Raad et 
al., 2017). 
The ESHRE guidelines suggest that as there is moderate evidence indicating 
associations between RPL and poor-quality sperm, and that there is evidence that 
lifestyle contributes, clinicians should alert couples to this, and possibly offer sperm 
DNA fragmentation tests if available (Atik et al., 2018). 
1.3.8.7 Progesterone/Luteal phase defects 
Some studies suggest that the use of progesterone supplements in RM patients 
decreases miscarriages (El-Zibdeh et al., 2005). In a Cochrane database review in 
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2013, a subgroup analysis of women with RPL (defined as 3 or more consecutive 
losses) treated with progesterone demonstrated a statistically significant decrease in 
miscarriage rate compared to placebo or no treatment. (OR 0.39;95% CI 0.21-0.72) 
(Carp et al., 2015). However, the PROMISE trial in 2015 found that the administration 
of progesterone in the first trimester did not result in a significantly higher rate of live 
births among women with a history of unexplained recurrent miscarriages 
(Coomarasamy et al., 2015). However, the trial did not perform genetic analyses of 
the products of conception in the losses, and may have missed a significant 
contributor to losses, that could have altered the findings. Furthermore, the trial may 
have had insufficient statistical power to detect a difference. Recently Coomarasamy 
et al., (2019) in a randomized controlled trial of progesterone in women with bleeding 
in early pregnancy, showed that the administration of progesterone did not result in a 
higher incidence of live births. However, in a subgroup analysis of women with three 
or more miscarriages and bleeding in early pregnancy, there was a suggestion of 
benefit from progesterone (Coomarasamy et al., 2019). This requires validation.  
1.3.8.8 Domestic violence 
Intimate partner violence and domestic violence have been associated with an 
increased risk of both induced and spontaneous miscarriages (Fanslow et al., 2008; 
Silverman et al, 2007). Complex social situations, especially among poorly educated 
and financially disadvantaged women, are prevalent and healthcare systems and 
physicians need to be cognizant of the link between violence and miscarriages. 
1.3.8.9 Smoking and alcohol 
Maternal smoking is known to be associated with adverse pregnancy and neonatal 
outcomes, including ectopic pregnancies, congenital abnormalities, preterm birth, 
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small for gestational age babies, placenta praevia and stillbirth (Leung and Davies 
2015; Zhang et al., 2010). There have also been reports of sudden infant death 
syndrome, as well as other problems during childhood (Leung and Davies, 2015). 
However, evidence regarding pregnancy loss is lacking but, given the adverse 
outcomes, couples may best be advised to stop (Atik et al., 2018). 
1.3.8.10 Obesity 
Maternal obesity is a risk factor for RPL and has a significant impact on female 
reproductive health overall (Pandey et al., 2010; Boots and Stephenson, 2011). A 
body mass index greater than 30kg/m2 has been evaluated as a risk factor for RPL 
and a higher prevalence of RPL was reported in obese women with such a BMI, 
compared to women with a normal BMI. (0.4% versus 0.1%; OR 3.51; 95% CI 1.03 – 
12.01) (Lashen et al., 2004; Boots and Stephenson, 2011). An increase in euploid 
miscarriages among obese women compared to women of a normal weight (58% 
versus 37%, relative risk RR 1.63; 95% CI 1.08-2.47) has also been found (Boots et 
al., 2014). Lo et al., (2012) demonstrated that BMI, female age, number of previous 
losses and ethnicity were significantly associated with pregnancy outcomes, and 
maternal obesity, as demonstrated by a BMI ≥30 kg/m2, was significantly associated 
with an increased risk of miscarriages, in couples with unexplained RPL (OR 
1.73;95%CI 1.06-2.83). The possible pathways for the association between obesity 
and pregnancy failure include an adverse impact on the development of the 
endometrium or an adverse effect on ovaries affecting the quality of oocytes and thus 
embryo viability/quality or a combination of both (Boots and Stephenson 2011). 
Cavalcante et al., (2019) found a positive correlation between obesity and RPL. The 
actual mechanisms are unknown, and interventions such as weight control have not 
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been adequately investigated in RCT’s. Obesity is associated with chronic 
inflammation associated with numerous inflammatory markers such as high levels of 
C-reactive protein and interlukein-6 (IL-6) (Grimstad and Krieg 2016). Other possible 
mechanisms are abnormalities in the hypothalamic-pituitary-gonadal hormonal axis 
(Calvacante et al., 2019). Given that maternal obesity is associated with RPL, women 
should be advised to strive for a healthy weight before embarking on a pregnancy, 
both for the prevention of RPL and to decrease the known pregnancy complications 
associated with obesity, such a gestational diabetes mellitus, and its complications 
for both mother and fetus (Atik et al. 2018). 
1.4 Conclusions 
Miscarriage is a complex and heterogeneous condition, and is a significant negative 
life event that has a major emotional impact on couples. When the losses become 
repetitive, the impact is intensified, and feelings of grief, anxiety and personal failure 
affect both partners. The psychosocial needs of couples affected by RPL need to be 
considered when planning care, and these couples need access to expertise, 
investigations and individualized treatment plans that will reduce their losses. These 
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CHAPTER 2: The Recurrent Miscarriage Clinic 
2.1 Background 
Traditionally, women with recurrent miscarriage have been offered various tests in 
order to identify the cause and to guide management. These have been in various 
clinical settings including primary care, fertility and obstetric services. This dedicated 
clinic was established to better serve the needs of women who have suffered 
recurrent miscarriage. 
This cohort of patients was recruited from the Recurrent Miscarriage Clinic at the 
Women’s and Children’s Hospital in Adelaide, South Australia, from 2009 until 2017.  
This study formed part of a Clinical Trial named the PAPO (Prediction of Adverse 
Pregnancy Outcomes) study, (Clinical trial number ACTRN12609000254291). The 
study was approved by the Women’s and Children’s Hospital Human Research 
Ethics Committee in North Adelaide South Australia, REC1481/6/09. The patients 
were informed about the research and written informed consent was obtained. They 
had an average of four visits during the work up, and many were followed in the 
subsequent pregnancy, in a single clinic. 
The purpose of the study was to offer as full an evidence based recurrent 
miscarriage work up as possible, given the paucity of research in the area, evaluate 
the findings, on an individual basis, and advise on the best method of treatment for 
the presumed causes/associations, so that the patients could achieve their objective 
of a live birth. 
There were 1532 patients referred to the Recurrent Miscarriage Clinic, of whom 480 
fitted the criteria of recurrent embryonic miscarriages, (losses at 10 weeks or less, 
75 
 
post the last menstrual period), as described before. The reasons for the exclusions 
included non-consecutive losses, proven genetic abnormalities, or unproven 
pregnancies based on recall alone. Patients who suffered both embryonic and fetal 
losses were only included if they had experienced 2 or 3 consecutive embryonic 
losses prior to their index visit. The recent European Society of Human Reproduction 
and Embryology (ESHRE) guidelines, however, have suggested that non-
consecutive losses could be included, and this would have increased the eligible 
numbers considerably (Atik et al., 2018). 
There were 283 women aged less than or equal to 35 years (≤35), and 197 greater 
than 35 years of age (>35). They were referred to the Recurrent miscarriage clinic if 
they had suffered two or more consecutive pregnancy losses, with the same partner. 
2.2 Work-up 
 
The patients were referred to the clinic approximately six weeks after the 
miscarriage. A full history was taken including past medical, surgical, obstetric and 
gynaecological history, as well as family history, social status and work environment, 
dietary habits, smoking habits, drug use and exercise. Weight and height 
measurements were also performed, and BMI calculated. A family history of losses, 
congenital abnormalities, and any major illnesses was included. Details of the 
previous losses included the dating of previous losses in order to ascertain if they 
were embryonic or fetal, and any history relevant to this, history of medical or surgical 
management of the losses. If they had not had an abdominal CT scan, MRI or 
previous laparoscopy, dye studies or Hysterosalpingo-contrast-sonography, 
(HyCoSy), they were offered a 3D Ultrasound with pelvic studies. 
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Partners were also asked for their relevant surgical and Medical History, as well as 
relevant family history. If the previous miscarriage products had been sent for genetic 
testing, and the result was an aneuploid loss, they were not included in the 
assessment unless they had previously had more than two consecutive genetically 
normal/unknown losses.  
2.3 Demographics 
2.3.1 Ethnicities 
 ≤ 35 years N (%) > 35 years N (%) 
Total 283 (59) 197 (41) 
Ethnicities    
Caucasian 224 (79.2) 166 (84.3) 
Indian 23 (8.1) 9 (4.6) 
Other Asian 15 (5.3) 9 (4.6) 
Middle Eastern 18 (6.4) 7 (3.6) 
African 3 (1.1) 7 (3.6) 
BMI   
Underweight < 20 0 0 
Healthy 20.1 – 24.9 148 (52.3) 116 (58.9) 
High > 25 135 (47.7) 81 (41.1) 
Body Mass index: BMI was calculated and recorded. 
Table 2.3.1: The Ethnic structure and BMI of the patients in the RPL clinic. 
Patients were divided into two age groups, ≤35 years of age or > 35 years of age at 
their first visit. The reason for assessing these patients in the different age groups 
was due to the well documented effect of maternal age on fetal loss, as described by 
Nybo Anderson et al., (2000). They reported a steep increase in fetal loss after the 
age of 40 years, which was already increased in the 30’s, but particularly after 35 
years of age (Nybo Andersen et al., 2000). Women attending the clinic are 
heterogeneous in their journeys and experience of multiple miscarriages. It soon 
became obvious that a systematic approach to their care was required. Therefore, 
the ASK TEAMS approach was developed and is the subject of this thesis. 
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This approach was used to ensure that all patients had the same tests, as opposed 
to random or incomplete work ups. Given the large number of tests, a simple 
acronym was helpful in reminding physicians to arrange the Ultrasounds, fasting and 
non-fasting bloods. Many Centres still offer a work-up based on outdated 
recommendations, and even the acronym will need to change as more evidence 




The acronym is “ASK TEAMS” and is as follows: 
A Age: A realistic discussion regarding the effects of age on reproductive 
potential was held with all couples, particularly those aged over 40. Patients were 
also offered an Anti Müllerian Hormone test as part of the work up, if they were 
prepared to arrange this separately, as it is not covered by the National Insurance 
(MEDICARE).  
S Structure: If they had not previously undergone a diagnostic laparoscopy, 
hysteroscopy, hysterosalpingogram, HyCoSy, CT scan of the abdomen/pelvis or MRI 
of the pelvis, they were offered a luteal phase 3D ultrasound for assessment of the 
uterus, to detect congenital uterine abnormalities, such as a unicornuate, bicornuate, 
septate or arcuate uterus. Acquired abnormalities such as fibroids, Ashermans 
syndrome, adenomyosis or endometriosis, as well as ovarian morphology were also 
investigated. 
K Karyotype: All patients were asked to consent to send the products of 
conception for karyotyping, particularly if they had more than one loss. This was not 
always possible. If an aneuploidy was detected, the miscarriage was not included in 
patient selection. Parental karyotyping was initially performed on all those attending 
the clinic; however, the yield was so low, that it was finally restricted to those in 
whom a translocation was detected in a previous miscarriage, or in those in whom no 
other possible cause had been found. 
T Thrombophilia: Initially all patients were offered a full thrombophilic screen, for 
both genetic and acquired thrombophilias. Recent evidence has suggested that 
screening for hereditary thrombophilias has a very low yield, given their low 
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prevalence in population, and so the screening was restricted to those with a strong 
family history of venous thromboembolism, (VTE) or those who had experienced any 
thromboembolic events prior to presentation (Davenport et al., 2014). While evidence 
is conflicting, clinicians in most countries now agree that thrombophilias are unlikely 
to be associated with embryonic losses, especially as maternal blood flow to the 
intervillous space of the placenta is only initiated after ten weeks when gestation 
enters the Fetal period (Jauniaux et al. 2000). The 2018 ESHRE guidelines do not 
recommend screening for hereditary thrombophilias unless the screening is 
performed in the context of a research project, or in women who have had thrombotic 
events. The clinical utility of the testing was judged as minimal and the harms of 
testing thought to outweigh the benefits (Atik et al., 2018). 
Thyroid issues such as subclinical hypothyroidism and the presence of thyroid 
antibodies could replace the Thrombophilia heading. 
E Endocrine: All patients were offered thyroid function tests, a 75g oral glucose 
tolerance test (OGTT), including insulin and prolactin levels. Reproductive hormone 
levels were not routinely tested, unless the patient presented with cycle irregularity, 
or features of the polycystic ovarian syndrome (PCOS). If PCOS was suspected from 
history or from the 3D ultrasound ovarian morphology, a full androgenic work-up was 
undertaken including sex hormone binding globulin levels, testosterone levels and 
the free androgen index. 
A Autoimmune: Antibody tests included thyroid peroxidase antibodies (TPO), 
anti-thyroid receptor antibodies (ATA), antinuclear antibody (ANA) titres. Extractable 
nuclear antibody tests were only performed if the ANA titres were high. 
Antiphospholipid antibodies were tested in order to detect the Antiphospholipid 
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syndrome. They comprised: Anticardiolipin antibodies IgG and IgM, Beta-2 
Glycoprotein 1 (B2GP1) antibodies and the lupus anticoagulant antibodies; the dilute 
russell viper venom test (DRVVT) and Kaolin clotting time (KCT). (Lockwood et al., 
2013). 
M Metabolic: Insulin levels were tested as part of the endocrine work up, as were 
the glucose levels, detecting elevated fasting glucose, impaired glucose tolerance or 
overt diabetes. Fasting homocysteine levels were also tested. 
S Specific: Vitamin D, B12 and serum folate studies were performed. Infectious 
screens were performed if there was a positive history of vaginal infections, such as 
chlamydia or bacterial vaginosis. A detailed nutritional history was obtained, and 
coeliac studies performed for a history of dietary intolerances.  Body mass index was 
calculated at the initial visit and recorded. A history of depression and anxiety was 
also sought, and relevant referrals made for a mental health plan, if they were 
deemed to have a significant problem in need of additional psychological support. 
Partners were included in the work up, as long as they had been the father of at least 
the previous two losses. Their work up included a detailed history, and a fasting 
blood work up. This included fasting homocysteine, glucose, insulin, Vitamin D, 
folate, and B12 levels. Karyotype was initially performed on all partners but was 
eventually limited to those in whom the previous pregnancy loss had yielded a 







Non-Fasting bloods Complete blood picture 
 AMH (Privately funded test) 
 +/- Karyotype - History dependent 
 Thyroid function tests - TSH T4 
 Thyroid antibodies 
 Anti-Cardiolipin antibodies 
 Beta 2 GP1 antibodies 
 Lupus anticoagulant –DRVVT, Kaolin clotting time 
 Antinuclear antibodies 
  
Fasting bloods Glucose tolerance test, 75g, with insulin studies 
 Homocysteine levels 
 Folate, Vitamin B12 and Vitamin D studies 
  
Structural tests 3 D Ultrasound/ HyCoSy/ MRI/ laparoscopy/ hysteroscopy 
  
Male  
Fasting bloods +/- Karyotype – History dependent 
 Glucose and insulin levels 
 Homocysteine levels 
 Vitamin D, B12 and Folate levels 
 
Table 2.3.2 Investigations in the RPL Clinic, 
 offered to both partners. 
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CHAPTER 3: Age  
 
The term that is used to describe a woman’s reproductive potential, as it relates to 
the quality of her oocytes and her own individual follicular depletion, is ovarian 
reserve. Serum Anti-Müllerian Hormone (AMH) levels are an ideal marker of a 
woman’s ovarian reserve, as AMH is highly correlated with the number of antral 
follicles remaining. (Visser et al., 2006; Barad et al., 2009). Fertility declines in the 
years preceding menopause, and the menstrual cycle becomes irregular, ultimately 
ceasing. There is significant individual variation in the age of menopause and, 
subsequently, also in the age of ‘subfertility’ (te Velde et al., 1998). Chronological age 
is thus a poor indicator of individual reproductive ageing and also of actual ovarian 
reserve (Faddy et al., 1998). 
Anti Müllerian Hormone levels are an indirect reflection of ovarian reserve, and levels 
known to correlate with the remaining number of antral follicles. (Gruitjers et al., 
2003; Kelsey et al., 2012). 
Severe endometriosis, pelvic inflammatory disease, ovarian surgery, various 
systemic illnesses, chemotherapy and possibly smoking are all known factors 
affecting ovarian reserve. (Faddy et al.,1997; Sharara et al.,1998). It is possible that 
such ‘sub fertility’ could play a role in miscarriages, and AMH levels could predict the 
live birth chances of patients attending the clinic (Lukaszuk et al., 2009). Therefore, 
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Anti-M€ullerian hormone levels in recurrent embryonic miscarriage patients are
frequently abnormal, and may affect pregnancy outcomes
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ABSTRACT
This prospective cohort study measured anti-M€ullerian hormone (AMH) levels in recurrent miscarriage
(RM) patients, compared them to a normal population, and assessed the pregnancy outcomes. The RM
patients demonstrated AMH levels that were significantly lower than the normal population, both in
women aged 35 years, and those aged >35 years. AMH percentiles were found to be significantly
lower in the study group of RM patients 35 years (p< .004) in the 5th and 50th percentiles, and in all
percentiles in women >35 years (p< .03), were compared to women from a normal population. Serum
AMH levels may reflect quality, and quantity of the remaining oocytes in these patients, and RM
patients may have a low ovarian reserve, and a potentially poor oocyte quality, as shown by low circu-
lating AMH. The evaluation of AMH levels in a RM work up may allow realistic counselling and possible
ART referral in RM patients.
IMPACT STATEMENT
 What is already known on this subject? There is some evidence to show that low AMH levels are
associated with recurrent miscarriages and this is thought to be due to a decreased oocyte quality. The
AMH levels are lower in the patients with endometriosis, and are often significantly higher in the patients
with polycystic ovarian syndrome. Both conditions are independently associated with miscarriages.
 What the results of this study add? Anti-M€ullerian hormone (AMH) levels were found to be sig-
nificantly lower in recurrent miscarriage patients, compared to a normal population. This may be
another factor contributing to miscarriages. The spontaneous pregnancy rates in the miscarriage
group significantly improved with increasing AMH levels. This may confirm that patients with low
AMH levels have poorer quality oocytes, and thus may be considered ‘sub-fertile’. It was also found
that the utilisation of assisted reproductive technologies (ART) to achieve a pregnancy was signifi-
cantly reduced in the groups with a higher serum AMH.
 What the implications are of these findings for clinical practice and/or further research?
Serum AMH levels should be offered to all patients as part of a recurrent miscarriage work up.
Detecting the low AMH levels and counselling the patients on these findings may allow them the
option of accessing ART. ART may have the ability to expedite conception rates, and with pre-implant-
ation genetic analyses, could possibly select the embryos with the greatest chance of survival. Further








Ovarian reserve is the terminology used to describe the exist-
ing number of follicles within the ovaries. Although serum
AMH levels are an indirect reflection of ovarian reserve, they
have already been shown to be highly correlated with the
remaining number of antral follicles, another indirect meas-
ure of ovarian reserve (Gruijters et al. 2003; Visser et al. 2006;
Barad et al. 2009; Hansen et al. 2011; Kelsey et al. 2012). Early
pregnancy losses are the most common complication of
human gestation, occurring in 50–75% of all women trying
to conceive (Petrozza 2006). Many of these losses occur
before or with the next expected menses. With the advent of
sensitive pregnancy detection kits available to the general
public, previously unrecognised losses are frequently
detected. With the losses that occur after the first missed
menstrual cycle, approximately 15–20% are spontaneous mis-
carriages or ectopic pregnancies (Petrozza 2006).
Approximately, 5% of couples trying to conceive will have
two consecutive losses, and approximately 1% of couples will
suffer three consecutive losses during their reproductive lives
which is unlikely to be due merely to chance since it has
been estimated that the probability of three consecutive
losses is 0.34% (Bopp and Seifer 1998; RCOG 2011; Petrozza
2012). Christiansen stated that a risk factor could be detected
in approximately 50% of couples experiencing pregnancy
loss, there was very seldom a single factor, and that the
majority of losses have a multifactorial background involving
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the interaction of multiple genetic and environmental risk
factors (Christiansen 2016). It is possible that some of these
patients may have low ovarian reserves, and poorer quality
oocytes. The purpose of this study was to assess the AMH
levels in patients attending a recurrent miscarriage (RM)
clinic, compare the results with those of a normal population,
and to document the subsequent pregnancies.
Materials and methods
Recurrent embryonic miscarriage patients attending a RM
clinic between June 2008 and May 2014 were included. They
were offered serum anti-M€ullerian hormone (AMH) testing, as
well as the routine investigations that are typically offered in
a RM clinic, which includes a 3D ultrasound, blood tests for
endocrine (thyroid, prolactin levels) metabolic (GTT and insu-
lin studies, homocysteine levels) autoimmune (thyroid anti-
bodies, antinuclear antibodies), obstetric antiphospholipid
syndrome, nutritional vitamins D and B, and folate, and a
karyotype of both partners. Women with at least two con-
secutive embryonic losses (less than 10 weeks from the last
menstrual period) were included (Kolte et al. 2015). An
informed consent was obtained from all of the patients.
The women were divided into two groups, those aged 35
years or younger, and those aged over 35, because of the
well-known effects of advanced maternal age (Nybo
Andersen et al. 2000).
AMH assay
The serum AMH was quantified by immunoassay at Clinpath
Laboratories using a DSL AMH generation II method
(Beckman-Coulter Anti-M€ullerian immunoassay).
The AMH levels were recorded and all of the pregnancy
outcomes documented, including those in each group who
did not achieve a pregnancy over a period of two years after
the test was done, and those who only had further preg-
nancy losses. These outcomes were documented for all AMH
levels (low, normal and high) in the two age groups. The
women were followed up in the clinic for two years to ascer-
tain whether they had achieved their pregnancy spontan-
eously or by ART and whether they had a live birth (LB).
Ethics approval
This study formed part of a Clinical Trial named the PAPO
(Prediction of Adverse Pregnancy Outcomes) study (Clinical Trial
Number ACTRN12609000254291). The study was approved by
the Human Research Ethics Committee REC1481/6/09.
Statistics
The serum AMH concentrations in these women were com-
pared with those from a healthy cohort using data obtained
with permission from Shebl et al. (2011). The 5th, 50th and
90th percentiles in the age groups 35 and >35 years were
compared, and data were analysed using the Chi-square test.
The pregnancy outcomes in the women from the RM clinic
who achieved an ongoing pregnancy, spontaneously or via
ART, with low (<10 pmol/L), medium (10.1–30 pmol/L) or
high (>30 pmol/L) serum AMH were compared by ANOVA
(SPSS Version 19, SPSS Inc., Chicago, IL).
Results
During the study period, 202 patients were offered AMH test-
ing, 182 women accepted, and 20 declined testing. Serum
AMH results in the miscarriage group were compared with
1105 women in a presumably healthy sub group. The 5th,
50th and 90th percentiles were compared in the two groups
– women aged 35 years, and women aged >35 years. The
ethnicities of the patients were: Caucasian 88%, African 3.4%,
Vietnamese/Chinese 3.4%, Middle Eastern 3.4% and Indian
1.7%. The numbers of losses ranged from 2 to 11. AMH centi-
les were found to be significantly lower in the study group
of RM patients 35 years (p< .004) and in those aged
greater than 35 years (p< .03), compared to women from a
healthy population (Figures 1 and 2).
The percentages of women with low, normal and high
serum AMH concentrations were assessed. Overall, 53.3% of
all patients tested had low serum AMH, 34.6% were in the
normal range and 12.1% were in the high range. In the
group of women aged 35 years, 41.2% had serum levels of

















Figure 1. Anti-M€ullerian hormone (AMH) levels in women aged 35 years, com-
pared to a normal (referent) population (data derived from Shebl et al. 2011, with
permission). The 5th, 50th and 90th percentiles were considered. The normal popula-


















Figure 2. AMH levels in women aged >35 years compared to a normal (refer-
ent) population. The 5th, 50th and 90th centiles were compared. The normal
population showed significantly higher levels in all centiles (p< 0.03).
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22% had high levels. PCOS had been diagnosed in 84% of
those with an AMH > 30 pmol/L.
The women aged >35 years had lower AMH levels com-
pared to women 35 years or less (p< .000) as would be
expected with 60.5% with low AMH, 33.3% with normal lev-
els, and 6% had high levels. PCOS had been diagnosed in
50% of those with AMH levels >30 pmol/L.
Pregnancy outcomes
Patient follow up showed that among women aged 35
years with low AMH levels, 21.4% were designated infertile;
in that they did not achieve a desired pregnancy over a two-
year period. Precisely, 27.3% only had miscarriages, resulting
in an overall LB in women with low AMH levels of 57.1%. Of
the latter, 43.7% were spontaneously conceived pregnancies,
and 56.3% utilised assisted reproductive technologies (ART).
In the women 35 years with normal AMH levels, 8% were
infertile, 26.1% had only miscarriages, and the overall LB rate
was 68%; 82.4% of which were spontaneous pregnancies,
and 17.6% were the result of ART (Table 1).
The higher rate of ART between the women with low and
those with normal AMH levels was statistically significant
(p< .002). The women with high AMH levels had a 13% infer-
tility rate, 25% pregnancy loss rate and an LB rate of 60%, all
following spontaneous conceptions (Figure 3).
In the women aged >35 years, with low AMH levels,
36.2% were infertile, and 52.3% of them experienced only
miscarriages. There was an LB rate of 30.45%, of which 47.6%
were spontaneous conceptions, and 52.4% were the result of
ART. Those women with normal AMH levels had infertility
rates of 28.9%, and ‘losses only’ of 55.6%. The overall LB rate
was 44.4%, of which 91.7% were conceived spontaneously
and 8.3% were the result of ART. The higher rate of ART in
women with low versus normal AMH levels was statistically
significant (p< .007) (Figure 4).
In the women with high AMH levels, there were no infer-
tile patients, ‘losses only’ 57.1%, and the LB rate was 42.85%,
and all were conceived spontaneously (Table 2). The LB rate
was reduced in all three AMH groups in women aged
>35 years, as would be expected, with the greatest losses
occurring in the women >35 with high AMH levels.
Discussion
Fertility trends in the twenty-first century are different from pre-
vious centuries, with many women choosing to delay the birth
of their first child until their mid-thirties, due to career choices,
divorces and re-marriages. Traditionally the ‘perimenopause’ is
described as the time when ovarian function declines, resulting
in clinical symptoms such as menstrual irregularities. It is
Table 1. Outcomes regarding infertility, pregnancies, pregnancy losses and deliveries in women
aged 35 years, in each of the AMH groups.
35 years; 37.4%; 68 10 pmol/L 10.1–30 pmol/L >30 pmol/L
Total % patients 41.2% (28) 38.8% (25) 22% (15)
No pregnancies achieved 21.4% (6) 8% (2) 13% (2)
Pregnancies 78.57% (22) 92% (23) 87% (12)
Spontaneous 50% (11) 78.3% (18) 100% (12)
ART 50% (11) 21.7% (5) 0% (0)
Miscarriages 27.3% (6) 26.1% (6) 25% (3)
Spontaneous 66.7% (4) 66.7% (4) 100% (3)
ART 33.3% (2) 33.3% (2) 60% (0)
Deliveries 57.1% (16) 68% (17) 75% (9)
Spontaneous 43.7% (7) 82.35% (14) 100% (9)
ART 56.3% (9) 17.65% (3) 0% (0)


















Spontaneous vs ART pregnancies per AMH group 
in women aged ≤ 35 years 
spont ART
Figure 3. Spontaneous pregnancies versus assisted reproductive technology
(ART) pregnancies in low, normal and high AMH groups, in women aged 35
years, in each of the AMH groups. The need for ART decreased in women in
normal and high serum AMH levels (p< 0.002). Spont: spontaneous pregnan-





















Spontaneous versus ART pregnancies per AMH 
group in women aged > 35 years
Spont ART
Figure 4. Spontaneous pregnancies versus ART pregnancies in low, normal and
high AMH groups in women aged >35 years. The need for ART decreased in
the normal and high AMH groups (p< 0.007). Spont: spontaneous pregnancies;
ART: assisted reproductive technology; L: low; N: normal; H: high AMH levels.
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thought to be due to the continuous loss of oocytes with age-
ing; however, in recent years, ART have identified the events
that precede menopause (Seifer and Naftolin 1998; Dolleman
et al. 2014). An accelerated deterioration of ovarian function
begins much earlier than previously thought, probably in the
mid-thirties (Bopp and Seifer 1998), and possibly earlier in some
women, often without obvious symptoms. While it is well estab-
lished that ovarian reserve declines with age (Nikolaou et al.
2002; Baird et al. 2005), the rate of this decline seems to vary
among individuals and depends on the family history, medical
history, as well as on various environmental and genetic factors.
Severe endometriosis, pelvic inflammatory disease, ovarian sur-
gery, various systemic illnesses, chemotherapy and possibly
smoking are all known factors affecting ovarian reserve (Faddy
et al. 1992; Sharara et al. 1998). It is possible that such ‘sub fer-
tility’ could play a role in miscarriages, and AMH levels could
predict the LB chances of patients attending the clinic
(Lukaszuk et al. 2014). It is not ethically possible to directly
measure ovarian reserve as this would involve an invasive and
potentially ovarian damaging biopsy. Studies have shown highly
significant positive correlations between AMH levels and the
ovarian reserve assessed by manual stereological counts of non-
growing follicles in ovarian tissue samples (Hansen et al. 2011).
Whether low AMH levels reflect the quantity and quality of the
remaining oocyte pool or not, has been widely discussed.
Lehmann et al. (2014) described AMH as a ‘valuable biomarker
of oocyte quality in IVF’. Irez et al. (2011) also showed that AMH
levels may predict the oocyte quality. Conversely, high levels
reflect the polycystic ovarian syndrome, and thus the metabolic
factors associated, such as hyperinsulinism, dyslipidaemia and
hypertension, may be independent risk factors for pregnancy
losses (Cocksedge et al. 2009).
Pils et al. (2016) and Atasever et al. (2016) both demon-
strated that AMH levels were significantly lower in the RM
groups compared to controls. Our findings suggest that a
low ovarian reserve may be a factor in RM patients, and as
such, should possibly be considered when offering assess-
ments of such couples, as the detection of low levels, particu-
larly in a younger patient, may be significant for their
pregnancy planning. Kedem et al. 2013, showed that it is
unnecessary to distinguish between low and extremely low
AMH levels, when counselling patients or referring them for
ART. They showed that both the low and extremely low AMH
group had similar pregnancy rates in IVF cycles (Kedem
et al. 2013).
The spontaneous pregnancy rates improved with increas-
ing AMH levels, this may suggest that patients with low AMH
levels have poorer quality oocytes and may thus be consid-
ered as ‘sub-fertile’ (Gnoth et al. 2005; Ebner et al. 2006).
Greenwood et al. 2017 found that patients with rigorously
defined infertility had AMH levels and antral follicle counts
(AFC) no different to community-based controls. Their find-
ings challenge the assumption that ovarian reserve is an indi-
cator of fertility. AMH correlates well with AFC in normo-
ovulatory IVF populations and is also strongly associated with
a poor ovulatory response to stimulation when low, and has
the ability to predict an excessive response to ovarian stimu-
lation when high (Greenwood et al. 2017). However, RM
patients may be an entirely different cohort with additional
factors contributing to decreased AMH levels, as well as
adverse pregnancy outcomes. Detecting the low AMH levels
and counselling the patients about these findings may have
increased the use of ART in this group. ART may have the
ability to expedite conception rates, and with pre-implant-
ation genetic analyses, ART could possibly select embryos
with the greatest chance of survival (Brezina et al. 2013). In
support of this concept, the need for ART was significantly
reduced in the groups with higher serum AMH. Detecting
high levels could alert the clinician to the possibility of PCOS
and its consequences.
The LB rate was reduced in all three AMH groups in the
women aged greater than 35 years, as would be expected;
with the greatest losses occurring in the women aged over
35 with high AMH levels. High levels at this age are more
likely to reflect the contribution of PCOS, and the consequent
metabolic disturbances that may be embryotoxic (Kdous
et al. 2009).
Strengths and limitations
This is a small study; larger studies are needed to confirm
these findings. AMH levels are not thought to be influenced
by the stage of the menstrual cycle, and as such AMH is an
excellent marker of ovarian reserve, allowing the clinician to
assess where the patient is in her reproductive lifespan. This
may be critical in patients experiencing miscarriages.
Conclusions
The patients attending a RM clinic may have a low ovarian
reserve, and potentially a poor oocyte quality, as shown by
low circulating AMH. Establishing the ovarian reserve early in
the work up allows the clinician to concentrate on possible
interventions that may expedite the patient’s journey towards
the goal of achieving a successful pregnancy. Women should
still undergo a full miscarriage work up, and any potential
contributing factors should be treated as expeditiously as
possible. Early detection allows a realistic counselling,
reassurance and relevant interventions in this traumatised
group of patients.
Table 2. Outcomes regarding infertility, pregnancies, pregnancy losses and
deliveries in women aged >35 years, in each of the AMH groups.
>35; 62.5% (114) 10 pmol/L 10.1–30 pmol/L >30 pmol/L
Total patients 60.5% (69) 33.3% (38) 6.2% (7)
Infertility 36.23% (25) 28.95% (11) 0
Pregnancies 63.77% (44) 71.05% (27) 100% (7)
Spontaneous 50% (22) 70.37% (19) 85.71% (6)
ART 50% (22) 29.63% (8) 14.29% (1)
Miscarriages 52.27% (23) 55.56% (15) 57.14% (4)
Deliveries 30.44% (21) 31.58% (12) 42.85% (3)
Spontaneous 47.62% (10) 91.67% (11) 100% (3)
ART 52.38% (11) 8.33% (1) 0
Low, 10 pmol/L; normal, 10.1–30 pmol/L; high, >30 pmol/L.
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Abstract
Background: Women who suffer recurrent miscarriage are a heterogeneous group. Known causes include genetic and endocrine
abnormalities, anti-phospholipid syndrome and autoimmune disease. Congenital uterine abnormalities (CUAs) such as bicornuate,
unicornuate, septate and arcuate uterine abnormalities are known to negatively impact on pregnancy rates, and to increase the
miscarriage rates of genetically normal pregnancies. In some countries, such as Britain, 3D ultrasound of the pelvis is offered
routinely to women with recurrent miscarriages.
Aim: To determine the prevalence of CUAs and other pelvic pathology, in women attending a South Australian recurrent
miscarriage clinic.
Materials and methods: 3D transvaginal ultrasounds performed during the luteal phase of the menstrual cycle were offered to all
patients attending the recurrent miscarriage clinic, who had not previously had a hysteroscopy, laparoscopy, HyCoSy or MRI study
of their pelvis. A Philips IUI 8 MHz transvaginal probe for freehand sweep, and dedicated 3D transvaginal probe was used. 3D
scans provide a coronal view of the uterus, ideal for detecting abnormalities which may be missed during routine conventional 2D
scanning.
Results: A total of 210 women were recruited, 200 results were available, and 29% were found to have a CUA. 15% had
polycystic ovaries detected, 15% were found to have fibroids, 12% adenomyosis and 1.5% Asherman’s syndrome.
Conclusions: 3D ultrasound evaluation of patients attending a recurrent miscarriage clinic detects CUAs, and has a high detection
rate of other pelvic abnormalities that may contribute to recurrent miscarriages.
Keywords: 3D ultrasounds, bicornuate uterus, congenital uterine abnormalities, recurrent miscarriages, septate uterus.
Introduction
3D ultrasound investigations may be used in conjunction with
2D ultrasounds for a full evaluation of the pelvis, so that struc-
tural abnormalities as well as ovarian, tubal, myometrial,
endometrial and cervical areas can be evaluated in a single
study period. 3D ultrasound is a non-invasive method of inves-
tigation that allows the uterine dimensions to be measured,
which helps in the diagnosis of congenital uterine abnormalities
(CUAs).1
Congenital uterine abnormalities have been thought to be a
cause of pregnancy loss and adverse pregnancy outcomes, and
the reported prevalence of these abnormalities in women
suffering recurrent pregnancy loss varies from 6% to 38%.2
CUAs are thought to result from abnormal formation, fusion
or resorption of the M€ullerian ducts during fetal life.1 Although
miscarriages are frequently caused by a genetic problem such as
an abnormal karyotype in the embryo or fetus, the parental
causes most likely to impact on a pregnancy are chromosomal
translocations, autoimmune diseases, endocrine or metabolic
disorders, uterine anomalies and age-related issues.3 The preva-
lence of major CUAs is thought to be at least threefold higher
in women with a history of recurrent miscarriages in both
embryonic (gestational age of 10 weeks or less from the last
menstrual period) and fetal (gestational age of greater than
10 weeks), compared with the low-risk population, and thus
CUAs may indeed be responsible for pregnancy loss in a signifi-
cant proportion of women with recurrent miscarriages
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(Figures 1 and 2).4 3D ultrasound was offered as part of the
work up in the RM clinic to ascertain if it could contribute
towards the assessment of these patients.
Materials and methods
This prospective cohort observational study formed part
of a Clinical Trial named PAPO (Prediction of Adverse
Pregnancy Outcomes) study (Clinical trial number
ACTRN12609000254291). The study was approved by the
Women’s and Children’s Hospital Human Research Ethics
Committee in North Adelaide South Australia, REC1481/6/09.
Informed and written consent was obtained from all partici-
pants. CUAs were classified in accordance with the modified
American Fertility Society Classification (Table 1).5
Women with a history of at least two consecutive miscar-
riages had 3D ultrasounds performed in the Women’s Ultra-
sound department in a tertiary referral hospital in Adelaide.
The scans were performed in the luteal phase of the menstrual
cycle using a Philips IU22 C8-4V freehand sweep +/ Philips
3D 9-3V with dedicated 3D vaginal probes, or GE Voluson E8,
RIC 5-9-D vaginal probe. 3D scans provide a coronal view of
the uterus, ideal for detecting the abnormalities that may be
been missed during routine conventional 2D scanning. Polycys-
tic ovaries may be detected on 3D ultrasound, as large volume
ovaries containing greater than 12 follicles each, measuring
from 2 to 9 mm in width.6 Adenomyosis is a non-neoplastic
condition characterised on ultrasound by the presence of
myometrial cysts or heterogeneous areas, diffuse vascularity,
asymmetry of the myometrial walls, and a globular or bulky
uterine configuration.7 HyCoSy was offered to the patients if the
uterine findings were unclear on the 3D scan alone. The sonog-
raphers are all employees at a Public Hospital offering Tertiary
Obstetric Ultrasounds, and all were reported by a Senior COGU
Specialist. The women also had the full routine miscarriage
investigations offered by the clinic, which include throm-
bophilic, endocrine, autoimmune, metabolic and genetic inves-
tigations (Table 2). The reason for dividing the patients into
two groups, ≤35 years and >35 years, is due to the independent
effect of maternal age on the risk of spontaneous abortion.8
Results
210 patients were offered a 3D ultrasound, 200 were available
for assessment and 10 were lost to follow-up. The ages of these
women ranged from 22 to 44 years of age, and they had had
from 2 to 15 losses prior to presentation. There were 108
Figure 1: A septate uterus on 3D ultrasound.
Figure 2: An arcuate uterus on 3D ultrasound.
Table 1: American Fertility Society (AFS) classification of M€ullerian
duct anomalies.
Class I Hypoplasia and agenesis. (a) vaginal, (b) cervical, (c) fundal,
(d) tubal, (e) combined
Class II Unicornuate. (a) communicating, (b) non-communicating,
(c) no cavity, (d) no horn
Class III Didelphys
Class IV Bicornuate. (a) partial, (b) complete
Class V Septate. (a) partial, (b) complete
Class VI Arcuate
Class VI Diethylstilbestrol (DES) drug related
© 2016 Australasian Society for Ultrasound in Medicine AJUM November 2016 19 (4) 143
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patients aged 35 years or less, mean 31 years, and 92 patients
aged 36 years or more, mean age 39 years. Primary miscarriage
was defined as ‘two or more consecutive miscarriages with the
same partner, without a live birth’. Secondary miscarriage was
defined as ‘two or more consecutive losses with the same part-
ner, after at least one live birth’.2 There were 92 primary
patients and 108 secondary patients. The majority of the losses
were embryonic losses prior to 10 weeks from the last men-
strual period, 10 had both embryonic and fetal losses, and one
had two fetal losses. Preterm labours (>20 weeks) were not
included.
Overall, 29% of the women presenting to the clinic had a
CUA. In women aged 35 years or less (≤35 years), 35.2% had
structural abnormalities detected. 7.9% had a bicornuate uterus,
2.6% had a unicornuate uterus, 57.9% had a septum (Figure 3)
and 31.6% were found to have an arcuate-shaped uterus. In the
women aged >35 years, 21.7% had structural abnormalities.
10% comprised a bicornuate uterus and there were no unicor-
nuate uteri detected, 65% had a septum and 25% had an arcuate
shape detected.
In women ≤35 years, 35.2% had a CUA detected as
described, and when these patients were evaluated according to
age and previous pregnancy status, 68.4% of them (primary
patients) had a CUA detected. In patients in this age group who
had a past live birth (secondary patients), 31.6% had a CUA
detected. There was a statistically significant difference in the
incidence of CUAs between the primary and secondary
patients, P = 0.04.
In women >35 years, 21.7% had a CUA detected, 35% of
these were in the primary group, and 65% were in the sec-
ondary group. In primary patients aged ≤35 years, the esti-
mated odds ratio for a CUA was 3.92 (95% CI 1.12–14.96)
compared to women aged >35 years.
Other findings included polycystic ovaries, fibroids, adeno-
myosis and Asherman’s syndrome, polycystic ovaries (greater
than 12 follicles per ovary, measuring 2–9 mm) were noted in
30 (15%) of the patients, 23 (21.3%) in women ≤35 years and 7
(7.6%) in women aged >35. An ultrasound detection of polycys-
tic ovarian morphology was correlated with endocrine findings,
before a diagnosis of polycystic ovarian syndrome was made.
Fibroids were detected in 30 (15%) of the patients, 8 (26.7%) in
the age group ≤35 years and 22 (73.3%) in the women aged
>35, as would be expected. One patient with fibroids also had
an endometrioma. Adenomyosis was diagnosed in 23 (12%)
patients presenting to the clinic, 13 (12%) in women ≤35 years
and 10 (10.9%) in women >35. Asherman’s syndrome was diag-
nosed in three patients in the clinic (Figure 4).
Discussion
3D ultrasound is a non-invasive method of investigation that
allows the uterine dimensions to be measured, which helps in
the diagnosis of CUAs.1 3D ultrasound is used in conjunction
with 2D ultrasound for a full evaluation of the pelvis, so that
structural abnormalities as well as ovarian, tubal, myometrial,
endometrial and cervical areas can be evaluated in a single
study period. The true population prevalence of CUAs is diffi-
cult to assess as the diagnostic tests are rarely applied to a low
risk population. A systematic review by Chan et al. showed a
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Figure 4: Other pathology detected at the time of the 3D ultrasound, in
women aged ≤35 years compared with those aged >35 years.
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prevalence of 5.5% in an unselected population, 8% in an infer-
tile population and 13.3% in women with miscarriages, and
24.5% in women with infertility and miscarriages.4 The limita-
tion of this study is the relatively small size, however, it has
demonstrated the usefulness of 3D ultrasound in the evaluation
of these patients.
In total, 72% of the patients who had a 3D ultrasound
were found to have uterine and/or pelvic abnormalities that
could have contributed to their pregnancy losses. In this
study, 29% of the patients presenting to the clinic who
underwent a 3D ultrasound were found to have a CUA. A
systematic review, evaluating the impact of congenital uterine
abnormalities on reproductive outcomes, showed that women
with canalisation defects, such as septate and subseptate uteri,
had the poorest reproductive performance.9 In addition to
having a reduced conception rate, they are at an increased
risk of first trimester miscarriage, preterm birth and fetal
malpresentation at delivery.
Previous studies of women suffering recurrent early preg-
nancy losses have shown a variable prevalence of CUAs. Salim
et al.2 detected a prevalence of 23.8% of all abnormalities, and
6.9% major abnormalities in 509 women with recurrent miscar-
riages. Clifford et al.10 found 1.8% major abnormalities in 500
cases. The prevalence in our study is broadly in agreement with
the findings of Salim et al.2 The lower finding by Clifford
et al.10 could have been the use of 2D ultrasound, which is
known to be less sensitive for the detection of these abnormali-
ties than 3D ultrasound.
Some studies have suggested that the pathophysiology of
early pregnancy loss in those patients with septate uteri may be
explained by the presence within the uterus, of a relatively avas-
cular septum, and thus the inability of this septum to provide
an adequate blood supply to the implanted and developing
embryo.11 Histological evaluation of some septae that showed
significantly reduced vascular supply in relation to the rest of
the uterus, supported this view.12 However, other studies have
suggested that there is an increased blood supply that interferes
with the implantation of the conceptus.13,14 Other causes may
be increased uterine contractions or reduced uterine capacity.
Salim et al.2 tried to quantify the degree of uterine distortion by
calculating the ratio between the fundal distortion and the
length of the cavity on hysterosalpinography. They found no
association between the severity of the uterine abnormality and
the number of previous miscarriages. In contrast, the results of
this study showed that the degree of distortion of the uterine
cavity in septate uteri was higher in women with recurrent mis-
carriages, compared to low-risk women, mainly due to a
reduced length of the unaffected cavity.
Some studies have reported an increase in adverse pregnancy
outcomes in women with an arcuate uterus, mainly second tri-
mester/fetal losses.4 The pathophysiology of miscarriage in
these women is unknown. However, other studies did not find
this association. The prevalence of an arcuate uterus in women
suffering recurrent miscarriages was 8.5% in our study, 6% in
the 35 and under age group, and 2.5% in those aged over 35.
Interestingly, these women were offered a hysteroscopy as part
of their assessment, and a small septum was detected in 4 of 12
cases that had not been detected even on 3D ultrasound. This
septum may have accounted for the losses.
Polycystic ovarian syndrome is a heterogeneous endocrine
disorder characterised by anovulation, hyperandrogenism,
infertility and metabolic dysfunction.6 Polycystic ovaries may
be detected on 3D ultrasound, as large volume ovaries contain-
ing greater than 12 follicles each, measuring from 2 to 9 mm in
width. However, the detection of ‘polycystic ovaries’ does not
establish a diagnosis of the polycystic ovarian syndrome, unless
other features are present, such as hyperandrogenism and
chronic anovulation. Recently, Dewailly et al.15 suggested that
PCOS should be defined as >25 follicles per ovary or ovarian
volume greater than or equal to 10 mL, depending on the avail-
able technology. However, for this study, performed prior to
this definition, the ‘12 follicles’ definition was used.
We detected ‘polycystic ovaries’ in 14 patients, but only eight
were finally confirmed as having the polycystic ovarian syn-
drome.
A recent study suggested that the prevalence of fibroids in
women experiencing recurrent pregnancy losses is about 8.2%.
This study showed that fibroids are associated with mid-trimester
losses among women with recurrent miscarriages. Resection of
fibroids associated with distortion of the uterine cavity can
eliminate the mid-trimester losses and result in a doubling of
the live birth rate.16 A prevalence of 15% was detected in the
whole group. Many of the fibroids were small and did not dis-
tort the uterine cavity. These patients were offered a referral to
a gynaecologist for a surgical discussion regarding the feasibility
of removal of the fibroids.
Adenomyosis is a non-neoplastic condition, affecting many
women, characterised by a benign invasion of the myometrium
by ectopic endometrium, that is accompanied by hyperplasia of
the adjacent smooth muscle.7 Such invasion may be detected
during a 3D ultrasound; however, there are insufficient studies
available to be able to assign causation. Endometriomas and
endometriosis may be detected by 3D ultrasound, however
there is conflicting evidence regarding surgical removal of
endometriomas, as such removal could damage the ovarian
reserve.17
Asherman’s syndrome is described as the presence of
intrauterine adhesions composed of fibrotic tissue, and is a
pathological condition that is thought to arise following trauma
to the basal layer of the endometrium, usually following a curet-
tage, infection or inflammation. Only three cases of Asherman’s
syndrome were detected, with significant synechiae. This was
lower than expected considering that many of the patients pre-
senting to a recurrent miscarriage clinic have had multiple
dilatations and curettage procedures, a known risk factor in the
development of this syndrome.18 Knopman et al. showed that
© 2016 Australasian Society for Ultrasound in Medicine AJUM November 2016 19 (4) 145
3D ultrasound findings in recurrent miscarriages
3D ultrasound was able to demonstrate the presence of Asher-
man’s syndrome, and identify the severity of the disease,
regarding the percentage of the uterine cavity that was
obstructed.19
Conclusion
This study demonstrates the usefulness of 3D ultrasound scans
in evaluating women suffering recurrent pregnancy losses. Lar-
ger studies are needed to confirm this. The information gath-
ered may be used to refer the patients to gynaecologists for the
hysteroscopic or laparoscopic evaluation of the uterus and pel-
vis, and possible removal of septae, synechiae or fibroids. The
ultrasound study should be performed during the luteal phase
following a miscarriage, in conjunction with the serological
workup, so that valuable time is not wasted in this vulnerable
group of patients.
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CHAPTER 5: Karyotype 
5.1 Introduction 
When the clinic initially opened, routine karyotyping of the couple was offered. 
However, the RCOG Guidelines in 2011 suggested that only couples in whom a 
translocation was identified in the products of conception should be evaluated, as the 
costs were excessive, especially given the prevalence in 1-5% of recurrent 
pregnancy losses (RCOG GT guidelines 2011). However, the American Society for 
Reproductive Medicine (ASRM) in 2012 recommended performing genetic 
karyotypes on both partners.  Popescu et al., (2018) proposed a new algorithm for 
the evaluation and treatment of recurrent pregnancy loss (RPL) based on the results 
of genetic testing obtained from the products of conception (POC) at the time of the 
next pregnancy loss. The algorithm suggests that couples with a single miscarriage 
should not have a work up performed, while those with two or more losses should 
have genetic testing of the POC performed. If the POC are found to be aneuploid, no 
further work up is required. If an unbalanced translocation is detected, both parents 
should undergo genetic testing. If euploid, a full recurrent  miscarriage work up 
should be performed (Popescu et al., 2018). 
The ESHRE Guidelines on Recurrent Pregnancy Loss (RPL) 2018, state that 
parental karyotyping is not routinely recommended in couples with RPL (Atik et al., 
2018). 
Currently our institution offers Karyotyping of the products of conception, and 




In the women aged ≤35 years, 254 had a karyotype performed. 11 women were 
found to have a translocation (4.3%). 164 men had a karyotype performed and 2 had 
translocations (1.2%). In the women aged > 35 years, 168 were karyotyped and 3 
translocations were found (1.8%). 110 of the partners were karyotyped and 1 carried 
a translocation (0.9%). 
Detection of an abnormal karyotype in either parent warrants a referral for genetic 
counsellors who have the ability to discuss pregnancy options with the couple, which 
could include assisted reproductive technologies with genetic testing of the embryos. 
Future pregnancy losses should be karyotyped, and if found to be euploid, other 
causes/associations should be investigated.  
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CHAPTER 6: Thrombophilia 
 6.1 Introduction 
When the recurrent miscarriage clinic first opened, a thrombophilic work up was 
routinely performed. As evidence accumulated suggesting that thrombophilias were 
unlikely to be a cause of early pregnancy loss in the embryonic group, we stopped 
routinely performing both the Factor V Leiden (FVL) and Prothrombin Gene Mutation 
genotype studies, unless there was a strong personal or family history of 
thromboembolism. MTHFR genpotyping was continued, along with a fasting 
homocysteine level until the Public Health system decided that MTHFR was not a 
significant thrombophilia, and ceased funding the test. We no longer perform the 
genotypes, even if the fasting homocysteine levels are high, as the treatment is the 
same regardless of the polymorphisms. However, MTHFR and fasting homocysteine 
results were available for 316 of the clinic patients. 
The American College of Obstetrics and Gynecology (ACOG) recommends testing 
for the inherited thrombophilias (Factor V Leiden, Prothrombin gene mutation, Protein 
C, Protein S and antithrombin III deficiencies) when a patient has a personal history 
of venous thromboembolism (VTE) in the setting of a non-recurrent risk factor (such 
as surgery) or has a first-degree relative with a known or suspected high-risk 
thrombophilia (The Practice Committee ASRM, 2012). The test result would then be 
used for potential treatment of the pregnancy woman during pregnancy and not for 
the prevention of adverse pregnancy outcomes. 
 6.2 Methods 
Patients presenting to the RPL clinic were offered the genetic thrombophilia testing 
until this was discontinued by SA Health. (All patients are however, offered testing for 
90 
 
the Obstetric Antiphospholipid Syndrome, initially thought to be an acquired 
thrombophilia, however this is now believed to be a placental damage issue, not a 
clotting issue, in patients with embryonic losses).  
6.3 Results 
The prevalence of Factor V Leiden heterozygosity (FVLh) in our women was 4.6%, 
and homozygosity (FVL H) 0.2%. Said et al.,  found prevalences of 5.3% and 0.05%, 
respectively, in an Australian antenatal population (Said et al., 2008). 
Prothrombin gene mutation (PGM G20210 substitution mutation F2 c20210G>A) 
prevalence was 2.4% in the clinic, and in Said et al. it was also 2.4%. 
MTHFR homozygosity for the 677 polymorphism was 15.49% in our group, and 
11.62% in the antenatal population (Said’s group.) (p = 0.046). However, MTHFR 
homozygosity for the 1298 polymorphism was 9.78% in our cohort and 9.98% in the 
general antenatal population (Said et al., 2008). Compound heterozygosity 






Genetic thrombophilias RM 
total N 
RM  N (%) Aus cohort 
N (Said et 
al.) 
N  % P 
FVL  Homozygous 419 1   (0.2) 2019 1  (0.1) NS 
FVL  Heterozygous 419 19 (4.5) 2019 107 ( 5.3) NS 
PGM Homozygous 419 0   2018 0        
PGM Heterozygous 419 10  (2.4)  2018 49  (2.4) NS 
MTHFR 677 Hetero 368 151 (41) 2014 870  (43.2) NS 
MTHFR 677 Homo 368 57 (15.5) 2014 23   (11.6) 0.046 
MTHFR 1298 Hetero 368 151 (41) 2014 84   (41.9)  NS 
MTHFR 1298 Homo 368 36  (9.8) 2014 201 (9.9) NS 
Compound Hetero 368 69   (18.8) 2014 404  (20.1) NS- 
NS =not significant 
Table 6.1 Comparison of polymorphisms for thrombophilia between the Recurrent 
Miscarriage clinic and a general Australian antenatal population* 
*Data from Said et al., 2008 with permission. 
 
6.4 Discussion 
The finding that MTHFR 677 homozygosity was higher in our population than in the 
antenatal population was reflected in the homocysteine levels in this group. MTHFR 
homozygous patients were more likely to have higher levels of homocysteine than 
patients without the polymorphisms. However, Atik et al., (2018), have concluded that 
the evidence associating raised homocysteine (Hcy) levels and RPL is inconsistent, 
and have thus suggested that it should not be routinely tested for in a RPL work-up.  
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CHAPTER 7: Endocrine 
7.1 Thyroid disease 
All patients had thyroid stimulating hormone (TSH) levels checked as well as free 
thyroxine (FT4) levels. In the age group ≤35 years, 9.25% were found to have clinical 
or sub clinical hypothyroidism. We considered TSH levels above 2.5mlU/L as 
subclinical hypothyroidism. In the age group >35 years, 11.22% had thyroid disease. 
This is higher than normally described in the literature, but was due to the inclusion of 
the subclinical hypothyroidism group.  Subclinical hypothyroidism in pregnancy has 
recently been defined as a TSH level above the pregnancy-related reference range 
with a normal serum thyroxine concentration. The majority of subclinical 
hypothyroidism is caused by autoimmune thyroiditis, but may be due to iodine 
deficiency in some areas (Lazarus et al., 2014). 
7.2 Hyperinsulinism 
We offered a 75g OGTT with insulin studies to all patients. 245 patients accepted 
this. There were 5 patients with impaired fasting glycaemia or impaired glucose 
tolerance. With respect to insulin, 123 patients were normal, and 122 were found to 
have raised fasting, two hour (2h) or both fasting and 2h levels. 6.5% had raised 
fasting levels, 26.3% had both raised fasting and 2h levels. 67.2% had only raised 2h 
insulins. This has not been previously described in the literature, as most studies 
focus on the fasting levels. We later found that such hyperinsulinism significantly 
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ORIGINAL ARTICLE
Do raised two-hour pre-pregnancy insulin levels confer the same risks of
developing GDM, as raised fasting levels, in recurrent miscarriage patients?
Catherine McCormacka,b , Shalem Leemaqza, Denise Furnessc, Gustaaf Dekkerc and Claire T. Robertsa
aRobinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia; bDepartment of Obstetrics, Women’s and
Children’s, North Adelaide, South Australia, Australia; cAdelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
ABSTRACT
This study questioned whether raised pre-pregnancy two-hour (2 h) insulin levels, measured in recur-
rent embryonic miscarriage (RM) patients via a 75 g Oral Glucose Tolerance Test (OGTT), are associated
with an increased risk of gestational diabetes mellitus (GDM) in a subsequent pregnancy. Patients had
a 75g OGTT and insulin levels evaluated (n¼ 170). 54.1% had normal glucose and insulin levels, 45.9%
had levels indicating hyperinsulinism (HI). In the 98 patients who achieved a pregnancy, the prevalence
of GDM was 3.7% in those without HI, and 35.7% in the patients who only had raised 2 h insulin levels.
While HI has been described as a risk factor for miscarriages only in relation to raised fasting (basal)
insulin levels, this study demonstrated that raised 2 h insulin levels predict an increased risk of GDM in
a subsequent pregnancy. Thus raised 2 h insulin levels likely confer a similar risk to raised fasting insu-
lin levels in RM patients.
IMPACT STATEMENT
 What is already known on this subject? Fasting hyperinsulinism is known to be associated with
an increased risk of gestational diabetes mellitus (GDM) in pregnancy. Hyperinsulinism, as
reflected by the fasting (basal) insulin levels >20mU/L, has been recognized as a risk factor for
recurrent miscarriages, particularly in patients with polycystic ovarian syndrome (PCOS), in the
World literature. Raised two-hour insulin levels have not been considered as a risk factor in the
literature before.
 What do the results of the study add? We have demonstrated a 10-fold increase in the develop-
ment of GDM in patients with fasting insulin resistance, and/or raised 2h insulin levels, and an almost
10-fold increase in patients with only raised 2h levels. 58.8% of the patients who subsequently devel-
oped GDM only had raised 2h levels and would have been missed with routine testing.
 What are the implications of these findings for clinical practice and/or further research? Our
study has demonstrated that GDM was three times more prevalent in the patients with only raised
2h levels, than in those only with raised fasting levels, reflecting insulin resistance/hyperinsulinism.
Insulin studies including 2h insulin levels are therefore an important factor to consider when work-
ing up these patients. Insulin studies pre-pregnancy may be useful in identifying women at risk of







Fasting hyperinsulinism is known to be associated with an
increased risk of gestational diabetes mellitus (GDM) in preg-
nancy. Hyperinsulinism, as reflected by the fasting (basal)
insulin levels >20mU/L, has been recognized as a risk factor
for recurrent miscarriages, particularly in patients with poly-
cystic ovarian syndrome (PCOS) (Boomsma et al. 2008; Glueck
et al. 2008; Wang et al. 2011). Some investigators have
shown an increased prevalence of insulin resistance in
women who suffer recurrent pregnancy losses (Craig et al.
2002). Gestational diabetes mellitus (GDM) and maternal
obesity have been shown to be independently associated
with adverse neonatal and maternal outcomes, and both
share metabolic characteristics such as hyperglycaemia,
increased insulin resistance and hyperinsulinaemia (Catalano
et al. 2012).
First we found that a significant proportion of our
patients undergoing investigations for recurrent miscar-
riages had markedly raised two-hour (2 h) insulin levels,
with normal fasting insulin and normal glucose levels.
Given that fasting hyperinsulinism is known to be
associated with an increased risk of gestational diabetes
mellitus (GDM) in pregnancy, we followed these patients
in a subsequent pregnancy to establish if raised 2 h levels
did in fact confer as similar a risk of developing GDM
as fasting hyperinsulinism. If so, it may be possible that
raised two-hour levels are also a risk factor for miscarriages
and should be routinely tested in a recurrent miscarriage
work-up.
CONTACT Catherine McCormack deemccormack@hotmail.com Adelaide Medical School, Obstetrics and Gynaecology, Robinson Research Institution,
Adelaide 5001, Australia; Adelaide Women’s and Babies Division, Women’s and Children’s Hospital, North Adelaide 5006, Australia
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We conducted a prospective cohort observational study as
part of the PAPO study. (Prediction of Adverse Pregnancy
Outcomes – ACTRN126090002542910).
Patients referred to the recurrent miscarriage clinic from
July 2010 until January 2013 were evaluated for possible
causes of recurrent miscarriages, including genetic, structural,
autoimmune, endocrinologic, thrombophilic, metabolic and
lifestyle factors. Patients were included if they had two or
more documented (positive bloods tests/ultrasound examina-
tions) losses with the same partner. Written informed consent
was obtained from each patient. They were then followed up
in a subsequent pregnancy. The study was approved by the
Hospital Ethics Committee. (REC1481/6/09).
Data collection
All patients had their tests performed at the same laboratory
and were included if all requested tests were performed. A
75 g oral glucose tolerance test (OGTT) was performed after a
10 h fast, and fasting and two-hour glucose and insulin levels
were recorded. Demographic information was collected dur-
ing the face-to-face visits with the physician, and BMI calcu-
lated. Patients’ body mass index (BMI) was determined as
weight divided by the height in metres squared. A BMI of
18–24.9 is regarded as normal, 25–29.9 as overweight and
30 as obese.
Insulin was measured using the Advia Centaur analytical
system. This insulin assay detects recombinant insulin ana-
logues in addition to endogenous insulin (Clinical and
Laboratory Standards Institute (CLSI) 2006). The fasting insulin
levels accepted as normal by our laboratory are 0–12mU/L.
We accepted the glucose:insulin ratio >4.5 and insulin levels
<20 mU/L as normal, and a glucose:insulin ratio <4.5 and
insulin levels 20 mU/L as fasting hyperinsulinism. Normal
two-hour levels in our laboratory are 10–40 mU/L. In our nor-
mal group the mean two-hour insulin levels were 25.88, and
so we used three standard deviations from this mean as our
cut-off for the diagnosis of two-hour hyperinsulinism
52.6 mU/L, as there are no guidelines in the literature.
GDM was defined as a fasting glucose greater than
5.5mmol/L, and/or a 2 h level >8.0mmol/L, following a 75 g
GTT, at 28weeks of gestation.
Statistical analysis
Univariate analyses were performed on maternal demograph-
ics including age, BMI, previous miscarriages and ethnicity,
comparing between women with and without hyperinsulin-
ism. The association between GDM and fasting and two-hour
insulin levels was examined using Fishers exact test, with fur-
ther analysis using Logistic regression adjusted for age, BMI
and ethnicity to estimate the odds ratios and corresponding
95% confidence intervals. R version 3.3.2 was used to per-
form the analyses and results are considered statistically sig-
nificant at 5% significance level (p< .05).
Given that the GDM prevalence in South Australia was
5.8% at the beginning of the study, we calculated that a
sample size of 90 patients would be needed to achieve 90%
power to detect a doubling of the GDM rate with alpha 0.05.
We had 98 patients who went on to achieve pregnancy and
live birth.
Results
Overall 182 patients were recruited. Twelve patients did not
complete the study, had incomplete results, or were already
pregnant at the initial test, and were not included. 170
undertook the required 75 g GTT and completed the study;
44 (25%) of patients did not achieve a pregnancy during the
data collection period; 28 (22.2%) had miscarriages, and 98
achieved a live birth (77.8%).
Women were predominantly Caucasian Australians
(Caucasian 81.8%, Indian 3.5%, Asian 4.7%, African 1.8% and
Middle Eastern 8.2%). The ages ranged from 19 to 45 years,
and the numbers of previous losses from 2 to 10 (Table 1).
92 (54.1%) patients were found to have normal glucose
and insulin levels. 78 (45.9%) were found to have raised fast-
ing levels and/or 2 h levels and 3 (3.8%) had impaired GTT’s.
In the group with increased insulin levels (hyperinsulinism/
insulin resistance; HI/IR), 8.9% had raised fasting insulin,
23.1% had raised fasting and 2 h levels, and 67.9% had raised
2 h insulin levels only, with normal glucose levels. The normal
fasting insulin levels ranged from 0.5 to 19mU/L, and the
raised (hyperinsulinism) levels ranged from 20 to 78mU/L in
the hyperinsulinism group (Figure 1). The 2 h insulin levels
ranged from 2.8 to 49mU/L in the normal group and from
60 to 370mU/L in the group with hyperinsulinism (Figure 2).
Ninety-eight patients achieved an ongoing pregnancy fol-
lowing the testing. In these pregnancies, in the group of
women with raised 2 h insulin levels who did not develop
GDM, the insulin levels ranged from 60 to 120mU/L, and in
the group who did develop it, insulin levels ranged from 62
to 170mU/L (Figure 3). The association between 2h HI and
GDM was significant (p¼ .0013).
There was a clear association between Ethnicity and HI
(overall p¼ .0026). Although the numbers in some of the
groups were small, nearly 79% of the women of Middle
Eastern origin had HI.
Table 1. Demographics of patients attending Recurrent Pregnancy Loss clinic.
RM Clinic No HI HI p value
N (%) 92 (54) 78 (46) –
AGE (years) 22–43 21–45 ns
Mean 33.8 33.7 ns
Miscarriages
Range 2–10 2–8 ns
Mean 3.20 3.22 ns
BMI (kg/m2)
20–24.9 48 (52) 29 (37) ns
25 44 (48) 49 (63) ns
Ethnicity 0.0026
Caucasian 83 (90) 56 (72)
Asian 5 (5) 3 (4)
Middle Eastern 3 (3) 11 (14)
Indian 1 (1) 5 (6)
African 0 (0) 3 (4)
Hi: Hyperinsulinism; ns: non-significant.
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Table 2 shows the prevalence of GDM in each group.
Overall, 38.6% in those with raised fasting and/or two-hour
levels developed GDM in a subsequent pregnancy. Of the
patients who developed GDM in the subsequent pregnancy
after the detection of abnormal insulin levels, 17.7% were the
group who only had raised fasting insulin levels, and 58.8%
were those who only had raised 2 h levels; 23.5% had both
high fasting and 2 h insulin levels. After correcting for age,
ethnicity and BMI, the risk of developing GDM with raised
fasting or 2 h insulin levels was increased by between 10 and
28-fold (Table 2).
Although we used a conservative three standard devia-
tions from the mean in our normal group to identify a cut-
off for our high two-hour insulin group, this could be
Figure 1. Pre-pregnancy fasting insulin levels in patients with and without hyperinsulinism. Hyperinsulinism was defined as insulin levels >20mU/L or a fasting glu-
cose to insulin ratio <4.5.
Figure 2. Pre-pregnancy 2-hour insulin ranges in patients with and without hyperinsulinism. Hyperinsulinism was defined in this study as a level >60mU/L.
Figure 3. Pre-pregnancy raised 2-hour insulin levels (hyperinsulinism). Women who developed Gestational Diabetes Mellitus in a subsequent pregnancy, versus
those with hyperinsulinism who did not.
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reduced to two standard deviations, which would probably
increase the detection rate of HI in women with subse-
quent GDM.
Discussion
Women who suffer recurrent miscarriage form a heteroge-
neous group. However, previous reports link insulin resist-
ance with recurrent miscarriage in a sub-set of patients
(Wang et al. 2011). We have demonstrated a 10-fold increase
in the development of GDM in patients with fasting insulin
resistance, and/or raised 2 h insulin levels, and an almost 10-
fold increase in patients with only raised 2 h levels. 58.8% of
the patients who subsequently developed GDM only had
raised 2 h levels and would have been missed with rou-
tine testing.
Most of the available literature considers hyperinsulinism
to be reflected only by the fasting (basal) levels. Wang et al.
(2011) considered the fasting, one, two and three-hour levels,
however the patients were in the first trimester of pregnancy.
They found a significant difference in both the insulin and
glucose levels at one, two and three hours of testing, even
when they excluded patients with polycystic ovarian syn-
drome (PCOS). They concluded that there is an increased
incidence of insulin resistance in recurrent miscarriage
patients, in the first trimester of pregnancy, and suggested
that only testing for fasting insulin and glucose in recurrent
miscarriage patients, would be inadequate to demonstrate
insulin resistance (Wang et al. 2011).
Jakubowicz et al. (2004) found that hyperinsulinaemia led
to reduced concentrations of insulin-like growth factor bind-
ing protein-1 (IGFBP-1) and glycodelin in early pregnancy,
thereby increasing the chance of miscarriages. Glycodelin is
an immunomodulatory protein involved in implantation, and
Glycodelin -A is found in abundant levels in the decidua in
early pregnancy. It plays an important role both in placental
development and fetomaternal defence. Abnormal levels are
associated with unexplained infertility and recurrent preg-
nancy loss (Glueck et al. 2008). Interestingly, insulin can nega-
tively regulate the concentrations of glycodelin and IGFBP-1,
and this may be the mechanism by which it increases the
risk of miscarriages.
Hyperinsulinemia may also increase the level of plasmino-
gen activator inhibitor-1 and induce villous thrombosis,
thereby reducing the blood supply to the placenta and lead-
ing to trophoblastic hypoplasia, resulting in miscarriage
(Gordon et al. 1995).
Lee et al. (2016) hypothesised that HI could cause an
uncontrolled diabetic-like state in the fetal environment
resulting in increased first trimester losses. High insulin levels
have been shown in vitro to increase the transport of glucose
by first trimester cytotrophoblasts independent of glucose
level probably by upregulation of the GLUT1 glucose trans-
porter system (Lee et al. 2016).
In conclusion, our study has demonstrated GDM was three
times more prevalent in recurrent miscarriage patients with
raised 2 h insulin levels than in those with raised fasting lev-
els, reflecting insulin resistance/hyperinsulinism. Insulin stud-
ies including 2 h levels are an important factor to consider
when working up these patients. This finding needs to be
replicated in other populations. A full work-up should be per-
formed on all patients, and all presumed ‘causes/associations’
of miscarriages addressed. Insulin studies pre-pregnancy may
be useful in identifying women at risk of having miscarriages
or developing GDM in a subsequent pregnancy and therefore
identify women who may benefit from early intervention,
such as diet and life style interventions.
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CHAPTER 8: Autoimmune 
8.1 Thyroid autoantibodies 
All patients had their thyroid autoantibodies tested. In the ≤35 year age group, only 1 
patient did not choose to have the test. 247 (87.6%) were normal and 35 (12.4%) 
were positive for thyroid autoantibodies. These patients also had thyroid function 
tests, and in the antibody positive group, 19 (54.3%) had thyroid disease, versus 7 
(2.8%) in the antibody negative group. 
In the women aged >35 years only 2 patients did not test, 177 (90.8%) were normal 
and 18 (9.2%) had thyroid antibodies. 77.8% of the women with thyroid antibodies 
had overt thyroid disease, as opposed to 8 (4.5%) of those without antibodies.  
 
  8.2 Antiphospholipid Syndrome 
Obstetric Antiphospholipid (antibody) syndrome (APS) refers to a specific situation in 
pregnancy that comprises recurrent early pregnancy loss or sporadic late loss with 
positive antiphospholipid antibodies (APL’s) - lupus anticoagulant, anti-β2-
glycoprotein 1, and anticardiolipin antibodies – without concurrent VTE (Leaf et al., 
2017).  It has been shown that circulating APL’s are one of the main risk factors in 7-
25% of early pregnancy losses and the prevalence in the population is 1-5% (Kutteh 
et al., 2014). It is now thought that early losses are mainly due to defective 
endovascular decidual trophoblast invasion. APS incidence has been found to be 15-
20% in couples with RPL, in comparison to only 5% in women without a history of 
adverse pregnancy outcomes (Kutteh et al., 2014). Abnormal early trophoblast 
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invasion and placental development comprise the most likely pathogenic 
mechanisms in obstetric APS. Studies have shown that APL’s can directly impede 
trophoblast invasiveness, diminish human chorionic gonadotrophin secretion and 
impair trophoblast differentiation and maturation (Kutteh 2016). Molecular studies 
have shown that APL’s inhibit the trophoblast cell adhesion molecules ([alpha]1 and 
[alpha]5 integrins, as well as E and VE cadherins) (Je and Giradi, 2004). APL’s 
activate complement on the trophoblast surface inducing an inflammatory response 
(Kutteh et al., 2014). Thus the most frequently observed histological abnormality in 
APS associated pregnancy loss, is defective decidual endovascular trophoblast 
invasion, rather than intervillous thrombosis (Ornoy et al., 2003). 
ESHRE guidelines on recurrent pregnancy loss recommend screening for APS after 
two pregnancy losses (Atik et al., 2018). 
8.2.1 Findings 
In the women in the ≤35 year age group, 2 did not test, 212 (75.4%) did not have 
antibodies, and 69 (24.6%) were positive for APL’s on at least two occasions, post 
pregnancy loss and 6-12 weeks after the initial positive test. In the women aged > 35 
years, 2 did not test, 149 were normal (77.4%) and 46 (23.6%) were positive for 
APL’s. These prevalences are in keeping with other recurrent miscarriage clinics. 
8.3 Discussion 
Atik et al., (2018) in the ESHRE guidelines strongly recommend that APS be tested 
in women who are diagnosed as RPL patients. The current recommendations are 
that women with 2 or more losses before ten weeks of gestation (embryonic losses) 
or 1 loss after ten week, should be tested. These tests should be repeated after 6-12 
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CHAPTER 9: Metabolic 
9.1 Homocysteine 
The confirmed association between increased circulating homocysteine 
concentration and neural tube defects (NTD), (Zetterberg, 2004) has led to the 
hypothesis that high concentrations of homocysteine might be toxic to the embryo, 
and lead to decreased fetal viability, in that environment. Recently there has been 
more emphasis on the likely role of epigenetic processes and DNA methylation that 
occur throughout gestation.  The molecular events that result in NTD due to folate 
deficiency are unknown but may include insufficient methylation of crucial 
metabolites in the developing embryo and/or abnormalities in neural cell proliferation, 
differentiation and apoptosis, which may be due to DNA nucleotide misincorporation 
that resulting from folate deficiency in rapidly proliferating cells (Govindaiah et al., 
2009). 
9.1.1 Findings 
Fasting Homocysteine was measured in women presenting to the clinic. 
 
Homocysteine >10 µmol/L N (%) >14 µmol/L N (%) 
Wild type 1 of 38 (2.6) 0 (0) 
677 heterozygous 7 of 66 (10.6) 2 of 66 (3.0) 
677 Homozygous 7 of 53 (13.2) 4 of 53 (7.6) 
1298 Heterozygous 9 of 67 (13.4) 0 (0) 
1298 Homozygous 3 of 33 (9.1) 2 of 33 (6.1) 
Compound Heterozygote 7 of 60 (11.7) 3 of 60 (5) 
 





Footnote: Homocysteine >10 µmol/L but < 14 µmol/L, or > 14 µmol/L 
Figure 9.1. Percentages of increased homocysteine levels in each MTHFR 
polymorphism group 
While a small percentage of patients without the MTHFR polymorphisms (wildtype)  
had raised fasting homocysteine levels, greater than 10µmol/L, none exceeded 14 
µmol/L. There was a tendency for homocysteine to increase as the polymorphisms 
increased, with women having both polymorphisms having the highest circulating 
homocysteine levels. We do test for it, and we also check the serum folate and B12 
levels. Supplementation is suggested, as well as lifestyle changes.  
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CHAPTER 10: Specific  
The ASK TEAMS approach allows for additional tests to be performed according to 
the individual histories of the patients. This could include a toxic or infectious screen, 
should such a history be elicited. Drug screens could also be offered, and every 
patient should be questioned about diet, psychosocial situations and domestic 
violence issues. We encouraged patients to attend with their partners if possible, 
given the profound effect of miscarriages on both partners. 274 partners (57%) of the 
480 women attended and did the tests an answered lifestyle questions. 
 10.1 Smoking 
Cigarette smoke contains a significant number of toxic substances, including 
polycyclic aromatic hydrocarbons, heavy metals, alkaloids, nitrosamines and others. 
These componds may damage the embryo, impair endometrial maturation, 
implantation and possibly even placentation (Dechanet et al., 2011). Any of these 
mechanisms could cause the increase in miscarriages noted by Xu et al., (2014). 
These associations are further increased according to the number of cigarettes 
smoked per day (Xu et al., 2011). Atik et al., (2018) suggest that couples with RPL 
should be informed of the possible negative impact on their pregnancy plans. 
Obtaining a smoking history is important, as well as having a discussion about 
cessation. All couples were asked about their smoking history, and were strongly 
advised to stop, even if only one was a smoker. 10.2% (28) of the men admitted to 
smoking and only 2.8% (25) of the women. 
 10.2 Nutrition 
Nutrition is also important, and many vitamin deficiencies such as folate and B12 
deficiencies, known to increase the risk of hyperhomocystinaemia and neural tube 
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defects in pregnancies, (Zetterberg, 2004), were detected, as well as vitamin D 
deficiency or insufficiency, during the work up. Australia fortifies bread making flour 
with folic acid, and good quality pre-natal vitamins are available. Many patients 
accessed the social media networks and started self treating with micronutrients long 
before presentation to the RM clinic. Many had visited Naturopaths and  Homeopathy 
practitioners, prior to their appointments. The couples were advised not to plan a 
pregnancy until all tests had been completed and possible contributory deficiencies 
had been identified, and dietary issues addressed. Some were referred to their GP’s 
for longer follow up and referral to nutritionists or dietitions if deficiencies were were 
deemed important. 
 10.3 Vitamins 
There is increasing evidence that a deficiency of Vitamin D increases the risk of all 
adverse pregnancy outcomes, including miscarriages, gestational diabetes, 
intrauterine growth restriction, and pre-eclampsia (Wei et al., 2014). Vitamin D is 
thought to affect embryo implantation, placental angiogenesis, oxidative stress, 
immune function, glucose homeostasis and endothelial function (Wei et al., 2014). A 
recent study showed that Vitamin D has a role in regulating T regulatory cells (Treg) 
and T helper 17 cells (Th17) (Ji et al., 2019). 
Fasting vitamin D (25OHD3) was routinely measured in both partners. 
Supplementation was advised if the levels were below those recommended. Vitamin 
D levels were defined as: Deficient below 50nmol/L, Insufficient as 50 – 74.9 nmol/L 
and Sufficient as ≥75 nmol/L (Kramer et al., 2014). 
Vitamin D has been shown to also affect male fertility via positive effects on sperm 
motility, and direct actions on spermatozoa and activation of the molecular pathways 
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involved in the acrosomal reaction, sperm capacitation and motility (De Angelis et al., 
2017). 
 10.4 Male factor 
The ‘male factor’ in RPL has been investigated in numerous studies, particularly in 
relation to sperm aneuploidy (Gil-Villa et al., 2010, Collodel et al., 2009, Zidi-Jrah et 
al., 2016).  When sperm from couples experiencing RPL was compared with sperm 
from couples without pregnancy loss, a lower percentage of normal sperm 
morphology, concentration and progressive motility was found in the pregnancy loss 
group compared to those without loss. Obviously, sperm quality may affect 
embryonic development by genetic, as well as epigenetic, mechanisms (Zidi-Jrah et 
al., 2016. Aitken et al.,2016). These sperm-borne epigenetic marks are, in turn, 
affected by a variety of paternal factors, including genotype, age, obesity, smoking 
and exposure to environmental contaminants (Aitken et al., 2016). Raised circulating 
homocysteine in men has also been shown to possibly be toxic to sperm and may 
negatively affect sperm parameters (Gil-Villa et al., 2010). 
The ‘Lifestyle’ questions that the men were asked included caffeine intake, drug 
habits, alcohol intake, smoking, exercise patterns. 251 patients had their BMI 
recorded and 165 of these were overweight or obese.  
Two hundred and seventy-four partners attended the clinic. Once their blood tests 
were available, a discussion was held regarding possible interventions, such as 
folate, vitamins B and D supplementation.  Of the 155 men who were tested for 
fasting homocysteine, 68.4% had raised levels. They were advised to improve 
lifestyles, including factors that affect sperm quality, such as decreasing caffeine, 
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alcohol, smoking, and increasing vitamin supplementation if needed, all factors also 
know to increase homocysteine levels. 
Only 1.8% admitted to illicit drug intake among the men. 
Interestingly, the discussion regarding lifestyles and the possible impact on 
pregnancy outcomes by the male partner was accepted with profound relief by the 
women, predominantly because the overwhelming belief in many societies that the 
woman is responsible for pregnancy loss. Whether this factor decreased their stress 
levels and was thus part of their success later on, remains to be investigated.  
Supplementing vitamin deficiencies and lowering homocysteine levels via 
supplementation with homocysteine lowering agents, as well as changes to diet and 
habits,  was offered, and a repeat blood check after a month. Once the levels were 
back to the accepted normal levels, they were encouraged to attempt the next 
pregnancy.  
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Association between vitamin D status and hyperinsulinism
Catherine McCormack , Shalem Leemaqz, Denise Furness, Gustaaf Dekker and Claire Roberts
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ABSTRACT
Aims: Some studies have suggested that vitamin D deficiency is associated with an increased
risk of first trimester miscarriages, others have suggested that it is associated with an increased
risk of hyperinsulinism/insulin resistance and the development of gestational diabetes.
Hyperinsulinism is also thought to increase miscarriages. We investigated the association
between vitamin D levels and hyperinsulinism in a cohort of recurrent miscarriage patients.
Methods: Patients undergoing miscarriage investigations had insulin and vitamin D levels tested.
Vitamin D levels were classified as: sufficient (75nmol/L), insufficient (50–74.9 nmol/L) or defi-
cient (<50nmol/L). Hyperinsulinism was assessed via a 75g oral glucose tolerance test (OGTT)
with insulin studies.
Results: One hundred and fifty-five patients underwent the testing. Hyperinsulinism was
detected in 58.3% of the vitamin D deficient group, 38.7% of the insufficient group, and 33.3%
of the sufficient group (chi-square p¼ .034). There were no significant associations between BMI
and vitamin D levels, or BMI and hyperinsulinism. Caucasians comprised 82% of the clinic, and
67% of these women had vitamin D insufficiency/deficiency. Noncaucasians comprised 18% of
the clinic but 89% of these patients had vitamin D insufficiency/deficiency.
Discussion: We found that insufficient or deficient vitamin D levels were significantly associated
with hyperinsulinism in these patients. Vitamin D deficiency is also thought to contribute to an
increased risk of adverse pregnancy outcomes including preeclampsia, preterm birth, small-for-
gestational-age gestational diabetes mellitus, and miscarriages. Larger level one trials are needed
to establish if increasing serum vitamin D levels prior to conception or in early pregnancy
improves adverse pregnancy outcomes.
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Vitamin D has been implicated as a modifiable risk fac-
tor for miscarriages, due to its function as an immune
modulator and because it may modify maternal
immune tolerance, without which the semiallogeneic
human fetus cannot survive. Andersen et al., found the
adjusted hazard of first-trimester miscarriage was
lower with higher vitamin D concentrations [1–5].
Vitamin D is classically involved in the regulation of
calcium homeostasis, directly via affecting intestinal
calcium and bone absorption, and indirectly by sup-
pression of parathyroid hormone (PTH) secretion. It
also has several well established “nonclassical” roles in
the immune system and in functional regulation of a
wide variety of cell types [6]. Accumulating evidence
has linked vitamin D deficiency with abnormal glucose
metabolism, thought to mainly occur via direct effects
of vitamin D, either on pancreatic b-cell function or on
insulin sensitivity [7–9]. Studies have shown lower vita-
min D levels in diabetic subjects compared to nondia-
betics [10–14]. Lu et al. in a meta-analysis of
observational studies involving 16,515 patients from
20 studies revealed that low vitamin D levels were
associated with a 45% increased risk of the develop-
ment of Gestational Diabetes Mellitus (GDM) [8].
Insulin resistance and the resultant hyperinsulinism is
known to increase the risk of gestational diabetes and
pregnancy loss, particularly in patients with polycystic
ovarian syndrome.
Subjects
Patients referred to a Recurrent Miscarriage Clinic in a
Tertiary Public Hospital. They were evaluated if they
had had two or three clinically recognized, consecutive
miscarriages, with the same partner.
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Materials and methods
Vitamin D testing was offered to all patients present-
ing to the recurrent miscarriage clinic, with the routine
blood work up. Vitamin D (25-hydroxy vitamin D)
assessment was performed using the Thermo
ScientificTM LC-MS system by SA Pathology. 155
patients also had a 75 g Oral Glucose Tolerance test
(OGTT) together with fasting and 2 h insulin levels
measured as well. Insulin was measured using the
Advia Centaur analytical system. This insulin assay
detects recombinant insulin analogs in addition to
endogenous insulin. The fasting insulin levels accepted
as normal by our laboratory are 0–12mU/L, we used
the glucose: insulin ratio <4.5 and insulin levels
20mU/L to diagnose fasting hyperinsulinism. Normal
2-h insulin concentrations in our laboratory are
10–40mU/L. Using 10–40mU/L gave a mean of 25.88
in our group of normal patients. We used three stand-
ard deviations from this mean as our cutoff for the
diagnosis of 2-h hyperinsulinism, 52.6mU/L, as there
are no guidelines in the literature.
BMI was calculated as weight in kilograms divided
by the height in meters squared, and 20–24.9 as nor-
mal BMI, 25–29.9 as overweight and 30 obese.
Vitamin D levels were defined as deficient below
50 nmol/L, insufficient as 50–74.9 nmol/L and sufficient
as 75 nmol/L [9].
Statistics
The association between hyperinsulinism, vitamin D
levels, BMI categories, and ethnicity were examined
using chi-squared test, or Fisher’s exact test where
appropriate. A Breslow-Day test was also performed to
assess the homogeneity of odds ratios between hyper-
insulinism and vitamin D levels across different BMI
categories. Statistical analyses were performed in R
3.4.1 [15].
Results
The vitamin D results for 294 patients were available
for assessment and 155 of these had 75 g OGTT’s.
Eighty-two% of the patients were Caucasian, and only
18% non-Caucasian, comprising Indian (5%), African
(1.9%), Middle Eastern (6.5%), and Asian (4.6%).
Vitamin D levels in recurrent miscarriage patients
were sufficient in 33% of Caucasians, and just 11% of
non-Caucasians (Figure 1). Hyperinsulinism was signifi-
cantly more common in recurrent miscarriage (RM)
patients who had vitamin D deficiency or insufficiency
(p¼ .034) (Figure 2) than in patients who had sufficient
levels, and this was independent of BMI (p¼ .41).
Vitamin D levels were also independent of
BMI (p¼ .09).
Discussion
We have demonstrated that a low serum concentra-
tion of vitamin D is associated with hyperinsulinism.
We have previously shown a significant increase in
GDM in RM patients with prepregnancy raised fasting
or 2-h insulin levels, in a subsequent pregnancy (sub-
mitted). The coexistence of vitamin D deficiency/
insufficiency with hyperinsulinism in RM patients
strengthens the link between insulin resistance and
poor vitamin D status. Furthermore, it may indicate
that improving vitamin D status and metabolic health
could have important benefits for women planning



















Figure 1. Vitamin D levels in Caucasian and non-Caucasian



















Vitamin D levels and hyperinsulinism
HI
HI
Figure 2. Vitamin D levels and hyperinsulinism. The risk of
hyperinsulinism increased with decreasing vitamin D levels. S:
sufficient; I: Insufficient; D: deficient vitamin D; HI:
hyperinsulinism.
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1 to 4% of a population of reproductive age couples
and is multifactorial in origin [16]. Women who suffer
recurrent miscarriages are a heterogeneous group.
Known causes include genetic and endocrine abnor-
malities, antiphospholipid syndrome, autoimmune dis-
ease and uterine structural abnormalities [16]. While
genetic factors are an important cause of losses, life-
style factors, many of which are modifiable, are signifi-
cant. Increased maternal age and increased
prepregnancy BMI are two such modifiable risk factors
[15–17]. Vitamin D insufficiency and deficiency in preg-
nant women is common worldwide, particularly in the
winter months, and vitamin D supplementation is
thought to be a public health strategy that could
improve both maternal and fetal outcomes [18].
Vitamin D is synthesized in the skin following sun
exposure and to a lesser extent is present in the diet
[18]. Dark skin pigmentation, cold climates with little
sun exposure, clothing that limits sun exposure, sun
screen, as well as inadequate diets, all lead to vitamin
D deficiency. This is not necessarily predictable. People
with darker skins are known to make less cutaneous
vitamin D than those with little pigmentation [18].
However, in countries such as Australia, with extremely
high incidence of malignant melanoma many people
tend to limit sun exposure. Hence, hypovitaminosis D
is increasing, and is suspected to be a public health
problem in many parts of the world [18].
Vitamin D deficiency is associated with type 2 dia-
betes mellitus in adults [8] while in pregnancy it has
been associated with an increased risk of preeclamp-
sia, GDM, preterm birth, small for gestational age
babies (SGA), as well as problems in infancy such as
rickets [8]. Alternative actions for vitamin D in preg-
nancy loss have been reported. Ota et al. [19] showed
that a high proportion of women with recurrent preg-
nancy loss had vitamin D deficiency citing its associ-
ation with increased cellular and autoimmunity. They
found that women with low vitamin D status had sig-
nificantly increased antithyroid antibodies (ATA) anti-
nuclear antibodies (ANA) and antiphospholipid
antibodies (APA) [17,18]. APA’s are known to cause
pregnancy loss [19], whereas ANA’s and ATA’s are
associated with losses [20].
We have demonstrated an association between
decreased vitamin D levels and hyperinsulinism, which
may suggest that vitamin D is a modifiable risk factor
for adverse pregnancy outcomes. Large, well designed
multicentre randomized controlled trials are required
to actually determine whether vitamin D supplementa-
tion in women with low vitamin D status reduces the
risk of adverse pregnancy outcomes.
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CHAPTER 11: Conclusions 
 11.1 General 
The ASK TEAMS Acronym is useful for clinicians who deal with RM patients, as it not 
only reminds them of the extensive tests needed, but also allows additional tests to 
be added for individual patients and will allow other investigations to be added as 
they are discovered and found to be useful. It is also a reminder that a ‘Team’ 
approach to these patients, such as additional psychological support, may be of 
benefit. RPL patients are not a static group, but one of the most focussed and 
desperate groups of patients that one can encounter. They are psychologically 
damaged and are looking for help, and have often been traumatized by the frequent 
lack of compassion afforded their plight in busy Emergency departments facing more 
serious issues. They are also some of the most loyal patients ever likely to attend 
clinics and follow all advice given. Many are desperate to try for pregnancy as soon 
as possible, frequently before much of the work-up is completed. Thus, every couple 
needs to be treated as individually as possible, while trying to keep within the bounds 
of a predetermined but potentially flexible work-up. 
Constant auditing of findings, investigations, outcomes and the latest evidence is 
essential, and offering these couples the best investigations of the current available 
evidence is a duty of all physicians attending these couples.  
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The European Society of Human Reproduction and Embryology (ESHRE) develops 
guidelines for clinical practice in Europe, to provide clinical recommendations in order 
to improve the quality of healthcare delivery within the field of human reproduction 
and embryology. These guidelines were produced after careful consideration of the 
scientific evidence available at the time of preparation of the document and are the 
most recent guidelines on this difficult but ubiquitous problem. However, the authors 
are quick to point out that adherence to them cannot guarantee a successful 
outcome, nor do they establish a standard of care for institutions. The ESHRE 
guidelines do not replace the healthcare professional’s clinical judgement, nor clinical 
decisions, which need to be made on an individual basis using their clinical 
knowledge and expertise, while considering the circumstances, wishes and 
conditions of each individual couple (Atik et al. 2018).  
Thus, running RM clinics and dealing with such couples is time consuming and 
requires dedication, especially with the vast amount of information, not necessarily 
accurate or safe, available via social media forums, blogs etc. The acronym 
approach has allowed a consistent approach to the potentially massive work up, and 
is modified regularly, especially if individual investigations are eventually deemed 
non-contributory, such as the thrombophilias. While the ESHRE guidelines no longer 
suggest investigating fasting glucose and insulin levels, our findings of a significantly 
increased risk of gestational diabetes in patients with hyperinsulinism has 
encouraged us to continue these investigations, and to strongly suggest to patients 
that they modify their lifestyle before embarking on their next pregnancy, if possible, 
which may or may not be directly linked to miscarriages, but which may have a 
profound impact on the morbidity of both mother and fetus and their future health. 
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Recurrent miscarriages are difficult to study in a research setting, especially as they 
are common but heterogeneous. While there has been a vast improvement in the last 
three years with dedicated recurrent miscarriage conferences, they remain in the ‘too 
hard box’ for large level one evidence randomized controlled trials. However, we 
believe that consensus reached by a large number of clinicians is of use in the 
interim, until such trials can be undertaken. 
AGE: 
One of the most important facts regarding the age of the patients is that miscarriages 
increase with increasing maternal age. It is essential that this discussion occurs early 
in the work up, so that patients are aware of the facts regarding their pregnancy 
outcomes, and can hopefully make informed choices, prior to embarking on difficult 
and costly journeys with little chance of success. 
Pregnancy at an advanced maternal age is increasing worldwide in both developed 
and developing countries, particularly via advances in assisted reproductive 
technology (ART) (Kahveci et al., 2018). Unfortunately concomitant co-morbidities 
such as hypertension and glucose intolerance also increase with age, and may 
contribute to miscarriages or adverse pregnancy outcomes. However, not all patients 
can conceive when they plan to do so. Some women may need an assessment of 
their ovarian reserve, as low reserves may not only contribute to poorer egg quality, 
but also to miscarriages. Lyttle Schumaker et al., (2018) showed a marked increase 
in miscarriages in spontaneously conceived pregnancies of women with markedly 
decreased AMH levels. Their rate was twice that of women with normal levels, 
suggesting that AMH levels are inversely associated with miscarriage risk (Lyttle 
Schumaker et al., 2018). 
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Serum Anti-Müllerian Hormone (AMH) levels are an ideal marker of a woman’s 
ovarian reserve, as AMH is highly correlated with the number of antral follicles 
remaining (Visser et al., 2006; Barad et al., 2009.  
Offering this test to patients with a view to referring them to ART in a timely fashion 




The use of the 3 D ultrasound proved beneficial in detecting abnormalities that could 
potentially be corrected surgically. 
 
KARYOTYPE 
Genetics is advancing at a rapid rate, and new techniques are becoming available 
every year. Each institution needs to evaluate what they can offer in a cost effective 
manner that will yield the most benefit to these patients. Our Institution does not offer 
chromosomal microarrays yet, as they believe that the Karyotype currently offers 
more than the arrays could. Ongoing audit is currently in place.  
THROMBOPHILIA 
When the clinic was first established, thrombophilias were thought to be a cause of 
miscarriages. However, this line of thinking has changed significantly since then. It 
was assumed that clotting in the placenta could lead to adverse pregnancy 
outcomes, therefore these women were treated with anticoagulants. 
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A systematic review by Skeith et al., in 2016, reported no benefit of low molecular 
weight heparin (LMWH) for prevention of pregnancy loss in women with hereditary 
thrombophilia and prior late (≥ 10 weeks) pregnancy loss (LBR LMWH versus no 
LMWH: RR 0.81; 95% CI 0.38-1.72; 5 RCTs; n=308) or recurrent early (< 10 weeks) 
pregnancy loss (LBR LMWH versus no LMWH: RR 0.97; 95% CI 0.80-1.19; 2 RCTs; 
n=66) (Skeith et al., 2016). 
A Cochrane review on anticoagulant treatment for women with RPL with or without 
hereditary thrombophilia combined nine RCTs including 1228 women with 
predominantly early losses. The reviewers reported no significant effect of treatment 
(aspirin, LMWH, LMWH + aspirin) compared to placebo. The risk ratio for live birth 
was 0.94 (95% CI 0.80-1.11; n=256) in the comparison of aspirin versus placebo, 
1.23 (95% CI 0.84-1.81; n=453; studies at high risk of bias included) for LMWH 
versus no treatment, and 1.01 (95% CI 0.87-1.16; n=322) for LMWH and aspirin 
compared to no treatment. In the comparison of LMWH versus aspirin the risk ratio 
for live birth was 1.08 (95% CI 0.93-1.26; n=239), in the comparison of LMWH and 
aspirin versus aspirin alone it was 1.11 (95% CI 0.94-1.30; n=327) (de Jong et al., 
2014). 
Given placentation and clotting issues, thrombophilias can only be associated with 
fetal losses, not embryonic ones (< 10 weeks from LMP), thus a good history is 
essential if treatment is to be considered.  
We changed from treating all women with genetic thrombophilias to only those who 
had had thrombotic events outside of pregnancy, or those with a fetal loss or 





Our findings of significantly raised insulin levels in a large number of patients 
independent of their BMI, and the subsequent increase in GDM in a subsequent 
pregnancy, has lead us to conclude that hyperinsulinism is an issue in these patients. 
Thyroid disorders were also common and were treated. Elevated prolactin was not 
routinely treated unless clinical symptoms were detected. 
AUTOIMMUNE 
Autoantibodies were tested, particularly the antiphospholipid syndrome. Thyroid 
antibodies were also tested, but only sub-clinical or clinical hypothyroidism was 
treated. Hyperthyroidism was also treated. 
METABOLIC 
A fasting 75g OGTT is offered to all patients, and detection of abnormal levels 
warrants a visit to their GP’s for long term lifestyle advice, and future health. 
SPECIFIC 
This area allows additional tests to be added as new evidence becomes available. 
Patients referred to recurrent miscarriage clinics are psychologically fragile and 
vulnerable. Pregnancy loss is classified as a significant life event, and ESHRE now 
suggests that that there is a need to study the emotional impact on men, as well as 
the women (Atik et al., 2018). Considerable time needs to be spent dealing with RM 
couples, reassuring them that it was highly unlikely that either of them was to blame 
for the losses, explaining the relative dearth of level one evidence regarding 
treatments, and explaining the possible tests that could be offered, as well as lifestyle 
changes that should be instituted if issues are detected. 
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While many of the findings were consistent with those of recurrent miscarriage clinics 
world-wide, some unique observations were made:  
a) AMH levels were found to be significantly lower than in a normal population. Thus 
many of these women would be compromised if they were to waste significant time 
prior to planning the next pregnancy, as AMH is a marker of ovarian reserve. 
b) Fasting and two-hour insulin levels were tested, and when compared to patients 
with normal insulin levels, women with raised two-hour insulin levels had a 10-fold 
increased risk of gestational diabetes in a subsequent pregnancy, whereas women 
with raised fasting levels had a 4-fold increase. Lifestyle interventions such as 
increasing exercise and decreasing carbohydrate intake may improve insulin levels. 
c) Low vitamin D levels were significantly associated with hyperinsulinism in 
miscarriage patients and Vitamin D needs to be supplemented in many patients.  
The raised two-hour insulin levels and the subsequent increased risk of gestational 
diabetes in these women has not been described before. If this factor is taken into 
consideration, it would suggest that instead of the quoted figure of 50% of recurrent 
miscarriage patients not having a ‘cause/association’ detected during a work-up, the 
actual number may be considerably less. Recent work by Vega et al., (2019) showing 
that elevated insulin levels were directly toxic, in vitro, to trophoblasts from first 
trimester, resulting in apoptosis, increased DNA damage and overall reduced cell 
survival, is interesting. It suggests that increased insulin may be associated with 
placental damage. They also showed that this effect was reduced by the addition of 
Metformin in vitro (Vega et al., 2019). 
While it is difficult to calculate the exact number, the women aged 35 years or less in 
whom no obvious cause/association could be found numbered 8 (2.8%), when APS, 
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CUA, Vitamin D levels, homocysteine levels and hyperinsulinism were all considered. 
In the women aged over 35 years, this number was 5 (2.5%). 
11.2 Findings 
 
Investigations Test N ≤ 35 - 283 >35 - 197 
  N (%) N (%) 
Age -low AMH 182 28 of 68 (41.2) 69 of 114 (60.5) 
Structure congenital uterine abnorms 331 48 (24.4) 25 (18.7) 
Karyotype 422 11 (4.3) 3 (3.3) 
Thrombophilia FVL heterozygous 399 11 (4.6) 8 (4.5) 
Thrombophilia PGM heterozygous 399 4 (1.7) 6 (3.4) 
Endocrine –thyroid 424 26 (9.2) 22 (11.2) 
Endocrine fasting hyperinsulinism 245 3 (4.1) 5 (10.6) 
Endocrine 2-hour hyperinsulinism 245 48 (64.9) 33 (70.2) 
Endocrine fasting and 2-hour HI 245 23 (31.1) 9 (19.2) 
Autoimmune- Thyroid antibodies 480 35 (12.4) 18 (9.2) 
Autoimmune – APS 476 69 (25) 46 (24) 
Metabolic-vitamin D insufficiency 363 72 (33) 61 (42) 
Metabolic- Vitamin D deficiency 363 61 (28.1) 39 (26.7) 
Metabolic ↑Homocysteine 423 95 (37) 59 (35.1) 
Specific MTHFR 677 Homozygous* 368 28 (13.7) 29 (17.8) 
Specific MTHFR 1298 Homozygous* 368 20 (9.8) 16 (9.8) 
* While MTHFR was originally viewed as a thrombophilia, it is no longer, and testing has ceased. 
Table 11.1. The final test results in the two age groups in the women attending the 
RM Clinic. 
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 11.3 Pregnancy outcomes 
In the women aged ≤35 years, 12.7% did not achieve a pregnancy within two years 
of attending the clinic, 12.5% had only losses and 87% achieved a live birth (LB) 
(76.3% of all attending the clinic). In the >35 years age group, 24.9% did not achieve 
a pregnancy, 25% had losses only and 75% achieved a LB.  
 
Figure 11.1 The pregnancy outcomes in the women attending the clinic. 
Research has shown that women who suffer recurrent miscarriages are at an 
increased risk of future cardiovascular disease of total coronary heart disease after 
adjusting for traditional cardiovascular risk factors (Oliver-Williams et al., 2013). The 
risk appears to be independent of BMI, hypertension, waist-to-hip ratio and white cell 
count (Parker et al.,2014). Thus, miscarriages may reflect a bigger picture of overall 
cardiovascular health, and as such, could be a primary health care issue with 
























Every institution dealing with RM patients should decide on their baseline tests, and 
these should be consistently applied to all patients. The ASK TEAMS approach suits 
a service in which there may be a large change-over of staff on a regular basis, 
especially if such a service does not offer pre-printed investigation forms or pre 
determined blood sets per diagnosis. A clear distinction between recurrent 
miscarriages and infertility is also essential, especially if the institution does not offer 
ART. Referring a patient to an infertility specialist may allow for male factors to be 
identified that may be contributing to miscarriages or delayed pregnancies. The 
World Conference on Recurrent Pregnancy losses is now in its 5th year, and the 
bringing together of physicians with an interest in this complex issue has opened the 
area for the exchange of ideas, and possible collaborations in the future. 
Recurrent miscarriage patients are a heterogeneous group, and research in this area 
is difficult, especially as many patients do not want to wait for the necessary large 
multicentered randomized and placebo-controlled trials that are so vital to being able 
to provide evidence-based investigations and interventions.It is essential, however, 
that these trials be performed on an international platform, so that, ultimately, we may 
all achieve the safest and best outcomes for these unfortunate patients. 
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Background: Recurrent embryonic miscarriage (RM) patients who presented to a 
recurrent miscarriage clinic were offered a structured work up. 
Aims:  
To identify presumed causes/associations of RM’s and streamline investigations. 
Methods: 
Women were included if they had had two or three embryonic losses (Gestational 
age of ≤10 weeks). 
Results: 
The testing that was developed and subsequent acronym, was as follows: 
Age: Antimüllerian Hormone testing was offered. 
Structure: Patients were offered a luteal phase 3D ultrasound of their pelvis. 
Karyotype: Although this was routinely performed initially, later evidence suggested 
that it should be restricted to the miscarriage products. Parental karyotyping was then 
undertaken if translocations were detected. 
Thrombophilia: Initially all patients were tested. However, as thrombophilias are no 
longer considered as causal in embryonic losses, testing was ceased. 
Endocrine: Thyroid function tests and prolactin levels were tested. 
Autoimmune: Thyroid antibodies and antiphospholipid antibodies were tested. 
Metabolic: Fasting Homocysteine levels, and a 75 g oral glucose tolerance test with 
insulin studies was offered, as well as vitamin D, Folate and B12 levels. 
Specific: Male partners were tested for factors in their lifestyles that could contribute 
to sperm DNA damage and possibly contribute to pregnancy losses. Tests included 
fasting glucose, insulin, homocysteine, vitamin D, Folate and B12 levels. Other tests 
were initiated according to the history of the patient, such as an infectious screen. 
Outcomes: After risk assessment, counselling and patient specific interventions, the 
subsequent live birth rates were 87% in those ≤35, and 75% in >35 years. 
Conclusions: The ‘ASK TEAMS’ approach facilitates a consistent work-up. Tests are 
adjusted as evidence accumulates regarding miscarriages causes/associations. Live 
birth rates are excellent following this approach. 
 
Background: 
Recurrent pregnancy losses are possibly one of the most frustrating areas of 
medicine, not only for the couples who suffer them, but also for the physicians 
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attempting to alleviate the situation. Despite considerable research, this 
heterogenous condition remains one of the commonest reasons for women 
presenting to Emergency Departments, and the causes are most likely the result of 
multiple interactions of genetic and environmental factors, many of which have yet to 
be elucidated.1  
Miscarriage is the term applied to the loss of a pre-viable baby and most institutions 
will consider miscarriage as a loss up to 20 weeks of gestation. Losses from the 
diagnosis of pregnancy until an estimated 10 weeks from the last menstrual period 
are termed embryonic losses, and those from 10-20 weeks are defined as fetal 
losses. Recurrent pregnancy loss is a heterogenous condition, with considerable 
confusion as to the numbers of consecutive losses required for the actual definition. 
The American Society for Reproductive Medicine (ASRM) has accepted 2 or more 
consecutive pregnancy losses as their definition2, whereas the European Society for 
Human Reproduction and Embryology (ESHRE) had previously used 3 or more 
pregnancy losses in their definition but they have changed this to 2 in the latest 
guidelines.3 
Pregnancy losses are the most common complication of humanreproduction , 
occurring in 50 - 75% of all couples planning a pregnancy.4 Many of these losses 
occur before or with the next expected menstrual period. With the advent of sensitive 
pregnancy detection kits available to the public, previously unrecognized losses are 
frequently detected. With the losses that occur after the first missed menstrual cycle, 
approximately 15-20% are spontaneous miscarriages or ectopic pregnancies.5 
Approximately 5% of couples trying to conceive will have two consecutive losses, 
and approximately 1% of couples will suffer three consecutive losses during their 
reproductive lives which is highly unlikely to be due purely to chance since it has 
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been estimated mathematically that that the probability of two consecutive losses 
should be in the region of 2.25% and that of three consecutive losses about 0.34%.6,7 
Aims: Recurrent miscarriages are associated with a plethora of presumed ‘causes’ 
and/or ‘associations,’ many of which are not evidence based. The aim of this study 
was to develop a structured approach to investigations in a dedicated clinic, to 
ensure consistency for these couples, and to facilitate comparisons with other 
miscarriage clinics for research purposes. Frequent literature reviews are necessary 
to update investigations and implement ‘evidence-based’ interventions for these 
couples in their endeavour to become parents. 
Materials and methods: 
Ethics approval: 
This study formed part of a Clinical Trial named the PAPO (Prediction of Adverse 
Pregnancy Outcomes) study, (Clinical trial number ACTRN12609000254291). The 
study was approved by the Women’s and Children’s Ethics Committee, 
REC1481/6/09. 
Patients were divided into two age groups, ≤35 years of age or > 35 years of age at 
their first visit. The reason for assessing these patients in the different age groups 
was due to the well documented effect of maternal age on fetal loss, as described by 
Nybo Anderson et al.6 They showed a steep increase in fetal loss after the age of 40 
years, which was already increased in the 30’s, but particularly after 35 years of age.6 
It became apparent that an acronym could be used to systematise the large number 




Women attending the clinic are heterogeneous in their journeys, needing pathways, 
tests, and a systematic method, so the ASK TEAMS approach was developed. 
The acronym is “ASK TEAMS” and is as follows: 
A Age: Patients were offered an Anti Müllerian Hormone (AMH) test as part of 
the work up, if they were prepared to arrange this separately, as it is not covered by 
the National Insurance (MEDICARE). AMH Assay: Serum AMH was quantified by 
immunoassay at Clinpath laboratories using a DSL AMH generation II method 
(Beckman-Coulter Anti-Müllerian immunoassay). Serum AMH concentrations in 
women attending the Recurrent Miscarriage Clinic were compared with those from a 
healthy cohort using data obtained with permission from Shebl et al.8  
S Structure: If they had not previously undergone a diagnostic laparoscopy, 
hysteroscopy, hysterosalpingogram, HyCoSy, CT scan of the abdomen/pelvis or MRI 
of the pelvis, women were offered a luteal phase 3D ultrasound for assessment of 
the uterus, to detect congenital uterine abnormalities, such as a unicornuate, 
bicornuate, septate or arcuate uterus. Acquired abnormalities such as fibroids, 
Asherman’s syndrome, adenomyosis or endometriosis, as well as ovarian 
morphology were also investigated. 
K Karyotype: All patients were asked to send the products of conception for 
karyotyping, particularly if they had more than one loss. This was not always 
possible. If an aneuploidy was detected, the miscarriage was not included in patient 
selection. Parental Karyotyping was initially performed on all those attending the 
clinic but the yield was so low, that it was finally restricted to those in whom a 
translocation was detected in a previous miscarriage, or in those in whom no other 
possible cause had been found. 
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T Thrombophilia: Initially all patients were offered a full thrombophilic screen, for 
both genetic and acquired thrombophilias. Recent evidence has suggested that 
screening for hereditary thrombophilias has a very low yield, given their low 
prevalence in the population, and so screening was restricted to those with a strong 
family history of venous thromboembolism (VTE) or those who had experienced any 
thromboembolic events prior to presentation.9 While evidence is conflicting, most 
Countries now agree that thrombophilias are unlikely to be associated with 
embryonic losses, especially as maternal blood flow to the intervillous space is 
initiated at ten weeks (Fetal period). The 2018 ESHRE guidelines do not recommend 
screening for hereditary thrombophilias unless the screening is performed in the 
context of a research project, or in women who have had thrombotic events. The 
clinical utility of the testing was judged as minimal and the harms of testing thought to 
outweigh the benefits.3 Acquired thrombophilias, e.g. antiphospholipid antibodies, 
were grouped under auto-immune conditions. 
E Endocrine: All patients were offered thyroid function tests, a 75 g oral glucose 
tolerance test (OGTT) including insulin and prolactin levels. Reproductive hormone 
levels were not routinely tested, unless the patient presented with cycle irregularity or 
features of the polycystic ovarian syndrome (PCOS). If PCOS was suspected from 
history or from the 3D ultrasound ovarian morphology, a full androgenic work-up was 
undertaken including sex hormone binding globulin levels, testosterone levels and 
the free androgen index. 
A Autoimmune: Antibody tests included thyroid peroxidase antibodies, anti-
thyroid receptor antibodies (ATA), antinuclear antibody (ANA) titres. Extractable 
nuclear antibody tests were only performed if the ANA titres were high. 
Antiphospholipid antibodies were tested in order to detect the Antiphospholipid 
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syndrome. They comprised: Anticardiolipin antibodies IgG and IgM, Beta-2 
Glycoprotein 1 (B2GP1) antibodies and the lupus anticoagulant antibodies; the dilute 
russell viper venom test (DRVVT) and Kaolin clotting time (KCT).10 
M Metabolic: Insulin levels were tested as part of the endocrine work up, as were 
the glucose levels, detecting impaired fasting glucose levels, impaired glucose 
tolerance or overt diabetes. Fasting homocysteine levels were tested as well due to 
the potential association with thrombophilias. 
S Specific: Vitamin D, B12 and folate studies were performed. Infectious 
screens were performed if there was a positive history of vaginal infections, such as 
chlamydia or bacterial vaginosis. A detailed nutritional history was obtained, and 
coeliac studies performed for a history of dietary intolerances. Body mass index was 
calculated at the initial visit and recorded. A history of depression and anxiety was 
also sought, and relevant referrals made for a mental health plan, if they were 
deemed to have a significant problem in need of additional psychological support. 
Partners were included in the work up, if they had been the father of at least the 
previous two losses. Their work up included a detailed history, and a fasting blood 
work up. This included fasting homocysteine, glucose, insulin, Vitamin D, Serum 
Folate, and B12 levels. Vitamin deficiencies may reflect poor lifestyle choices, and 
have been associated with sperm DNA damage, thought to contribute to losses. 
Karyotype was initially performed on all partners but was eventually limited to those 
in whom the previous pregnancy loss had yielded a translocation on Karyotyping.11 
There were 1532 patients referred to the Recurrent Miscarriage Clinic, 480 of whom 
fitted the criteria of recurrent embryonic miscarriages, (losses at <10 weeks, post the 
last menstrual period). The reasons for the exclusions included non-consecutive 
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losses, proven genetic abnormalities, or unproven pregnancies based on recall 
alone. Patients who suffered both embryonic and fetal losses were only included if 
they had experienced 2 or 3 consecutive embryonic losses prior to their index visit. 
The recent European Society of Human Reproduction and Embryology (ESHRE) 
guidelines in 2018, however, have suggested that non-consecutive losses could be 
included, and this would have increased the eligible numbers considerably.3,12 There 
were 283 women aged less than or equal to 35 years (≤35), and 197 greater than 35 
years of age. 
The Clinic accepted referrals of patients/couples deemed to have had recurrent 
miscarriages. A detailed history was obtained. The patients were asked to have two 
sets of tests performed, one fasting, and the other non-fasting. If they had not had a 
3-Dimensional ultrasound (3D), laparoscopy, hysteroscopy, HyCoSy, MRI or CAT 
scan of the pelvis, they were offered a luteal phase 3D ultrasound scan. BMI was 
calculated, and Ethnicity recorded. 
Most patients required 2 or 3 visits. The first visit was used to obtain a detailed 
history and to plan the tests. The second visit was used for a review of the results, 
and to give the patient and partner a detailed plan of intervention, if needed, 




Investigations – Table 1 
Table 1 The current investigations offered to couples presenting to the RM clinic. 
FEMALE:  
Non-Fasting bloods Complete blood picture 
 AMH (Private test – incurred fees) 
 TSH, T4 
 Thyroid Autoantibodies 
 Anti-cardiolipin IgM and IgG antibodies (+ on 2 
occasions) 
 Beta 2 GP1 antibodies (+ on 2 occasions) 
 Lupus Anticoagulant – DRVVT and Kaolin clotting time (+ 
x 2) 
 Karyotype (if POC* abnormal) 
  
Fasting Bloods 75 g Oral Glucose Tolerance Test with insulin studies 
 Fasting Homocysteine levels 
 Serum Folate, vitamin B12 and vitamin D levels 
  
3D Pelvic Ultrasound  
  
MALE: Karyotype (if POC* abnormal) 
 Fasting Glucose and Insulin levels 
 Fasting Homocysteine levels 
 Serum Folate, vitamin B12 and vitamin D levels. 
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POC – Products of Conception 
 
Results: 
Age: - Serum Anti Müllerian Hormone levels were performed. 41.2% of women ≤35 
years had low levels (concentration??), 36.7% were normal (concentration range??) 
and 22.1% had high (concentration) levels. In women aged >35 years, 60.8% had 
low levels, 33.3% were normal and 6.1% had high levels. 
Structure: - 24.2% of women aged ≤35 years had congenital uterine abnormalities 
detected by 3D ultrasound as did 18.7% of those > 35 years. 
Karyotype: - 4.3% of the women aged ≤35 years had abnormal karyotypes, as did 
1.8% of women >35 years. 
Thrombophilias: - Testing was initially routinely performed but it was later 
discontinued.  
Endocrine: - 54.8% of women aged ≤35 years had insulin levels tested and 47.7% of 
those had hyperinsulinism detected. The fasting insulin levels accepted as normal by 
our laboratory are 0-12mU/L. We accepted the glucose:insulin ratio >4.5 and insulin 
levels <20mU/L as normal, and a glucose:insulin ratio <4.5 and insulin levels 
≥20mU/L as fasting hyperinsulinism. Normal 2 h levels in our laboratory are 10-
40mU/L. In our normal group the mean 2 h insulin levels were 25.88mU/L, and so we 
used three standard deviations from this mean as our cut-off for the diagnosis of 2 h 
hyperinsulinism (52.6mU/L), as there are no guidelines in the literature. 45.7% aged 
>35 were tested and 52.2% of those had increased insulin levels. 
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Autoimmune: - 12.4% of women tested aged ≤35 years had positive thyroid 
autoantibodies and 54.3% of these women had thyroid problems. 9.2% of women > 
35 years had thyroid autoantibodies and 77.8% had thyroid problems. The obstetric 
antiphospholipid syndrome was detected in 22% of women aged ≤35 years and 19% 
of those > 35 years. 
Metabolic: - Vitamin D levels, as 25(OH)D3, were tested in 75% of women; 35.8% 
were sufficient (>75nmol/L), 36.6% were insufficient (>50nmol/L-75nmol/L), and 
27.6% were deficient (>50nmol/L). 
Specific: - Infectious screen if relevant, other tests according to history. 
Sub-clinical hypothyroidism was treated with low dose thyroxine, Vitamin D, B12 or 
Folate deficiency with supplementation. Raised Homocysteine levels were treated 
with dietary advice such as decreasing caffeine, alcohol and smoking, as well as 
supplementation with folic acid and vitamin B12 if they were found to be low. If 
positive antiphospholipid antibodies were detected, a second test was required, with 
a minimum time of 6-12 weeks for the repeat test, before the diagnosis could be 
established. Once the obstetric antiphospholipid syndrome (OAPS) was diagnosed, 
the patients were advised to start low dose aspirin until they were pregnant, and once 
pregnancy was confirmed, Heparin Sodium was added. Raised insulin or glucose 
levels were discussed and patients were frequently referred to dietitians for advice. 
Patients found to have abnormal Karyotypes were referred to Geneticists, and those 
with abnormal uterine findings, to gynaecologists, if surgical intervention was 
considered. 




Table 2 Results of the investigations of couples who presented to the RM clinic. 
The final test results in the two age groups in the women attending the RPL Clinic. 
Investigations Test N ≤ 35 - 283 >35 – 197 
  N (%) N (%) 
Age -low AMH 182 28 of 68 (41.2) 69 of 114 (60.5) 
Structure congenital uterine abnorms 331 48 (24.4) 25 (18.7) 
Karyotype 422 11 (4.3) 3 (3.3) 
Thrombophilia FVL heterozygous 399 11 (4.6) 8 (4.5) 
Thrombophilia PGM heterozygous 399 4 (1.7) 6 (3.4) 
Endocrine –thyroid 424 26 (9.2) 22 (11.2) 
Endocrine fasting hyperinsulinism 245 3 (4.1) 5 (10.6) 
Endocrine 2-hour hyperinsulinism 245 48 (64.9) 33 (70.2) 
Endocrine fasting and 2-hour HI 245 23 (31.1) 9 (19.2) 
Autoimmune- Thyroid antibodies 480 35 (12.4) 18 (9.2) 
Autoimmune – APS 476 69 (25) 46 (24) 
Metabolic-vitamin D insufficiency 363 72 (33) 61 (42) 
Metabolic- Vitamin D deficiency 363 61 (28.1) 39 (26.7) 
Metabolic ↑Homocysteine 423 95 (37) 59 (35.1) 
Specific MTHFR 677 Homozygous* 368 28 (13.7) 29 (17.8) 
Specific MTHFR 1298 Homozygous* 368 20 (9.8) 16 (9.8) 
* Footnote: While MTHFR was originally viewed as a thrombophilia, it is no longer, and 
testing has ceased.  
 
Discussion: 
The Royal Australian and New Zealand College of Obstetrics and Gynaecology 
utilizes the Royal College of Obstetrics and Gynaecology Green Top Guidelines 
regarding recurrent miscarriage investigations, dated 2011. They need updating. The 
European Society of Human Reproduction and Embryology (ESHRE) develops 
guidelines for clinical practice in Europe, to provide clinical recommendations in order 
to improve the quality of healthcare delivery within the field of human reproduction 
and embryology. These guidelines are produced after careful consideration of the 
scientific evidence available at the time of preparation and are the most recent 
guidelines on this difficult but prevalent problem. However, the authors are quick to 
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point out that even strict following of them does not guarantee a successful outcome, 
nor do they establish a standard of care that supersedes individual institutions. They 
do not override the healthcare professional’s clinical judgement, or clinical decisions, 
which need to be made on a case-by-case basis using their clinical knowledge and 
expertise, while considering the circumstances, wishes and conditions of each 
individual couple.3 Thus, running these clinics and dealing with such couples is time 
consuming and requires dedication, especially with the vast amount of information, 
not necessarily accurate or safe, that is available via social media forums, blogs etc.  
The acronym approach allows a consistent and systematic approach to the 
potentially massive work up, and is modified regularly, especially if individual 
investigations are eventually deemed non-contributory, such as the thrombophilias. 
While the ESHRE guidelines no longer suggest investigating fasting glucose and 
insulin levels, our findings of a significantly increased risk of gestational diabetes in 
patients with hyperinsulinism has encouraged us to continue these investigations. 
We strongly suggest to patients that they modify their lifestyle before embarking on 
their next pregnancy, if possible, which may not be directly linked to miscarriages, but 
which may have a profound impact on the morbidity of both mother and fetus. 
Recurrent miscarriages are difficult to study in a research setting, especially as they 
are common but heterogeneous. While there has been a vast improvement in the last 
three years with dedicated ‘World Recurrent Miscarriage Conferences’, they remain 
in the ‘too hard box’ for large level-one evidence randomized controlled trials. 
However, we believe that consensus reached by a large number of clinicians is of 
use in the interim, until such trials can be undertaken. 
The ASK TEAMS approach has systematised the work up for RM patients and made 
it consistent between patients. It facilitates appropriate and timely interventions and 
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counselling for these women and has resulted in more than acceptable live birth 
rates. 
Acknowledgements: 
We thank the patients for participating in this study. We thank Fertility and Sterility 
(Elsevier) for permission to use AMH data from a healthy cohort (Shebl et al. 2011). 
References: 
1) Christiansen OB. 2016. Foreword in: Recurrent Pregnancy Loss. Evidence-Based 
Evaluation, Diagnosis and Treatment Bashiri A, Harlev A, Argarwal A editors. 
Springer. DOI 10.1007/978-3-319-27452-2. 
2) Practice committee for the American Society for Reproductive Medicine.  
Definitions of infertility and recurrent pregnancy loss; A committee opinion. Fert 
Steril 2012;99:63. 
3) Atik RB, Christiansen OB, Elson J, Kolte AM, Lewis S, Middledorp S, et al. 
ESHRE guideline: recurrent pregnancy loss. Human Reprod open 2018. 
4) Petrozza JC. Early Pregnancy Loss. eMedicine. 
2006. http://wwwemedicinecom/med/topic3241htm 
5) Petrozza JC. Recurrent early pregnancy loss. January 2011. 
http://www.emedicine.medscape.com. 
6) Nybo Andersen AN, Wohlfahrt J, Christens P, Olsen J Melbye M.Maternal age 
and fetal loss:population based register linkage study. BMJ 2000;320:1708-12. 
7) Royal College of Obstetricians and Gynaecologists. The investigation and 
treatment of couples with recurrent first-trimester and second trimester 
miscarriage. In: Green-top guidelines No17. London: Royal College of 
Obstetricians and Gynaecologists; 2011. 
131 
 
8) Shebl O, Ebner T, Sir A, Schreier-Lechner E, Mayer RB, Tews G, et al. Age-
related distribution of basal serum AMH level in women of reproductive age and a 
presumably healthy cohort. Fertility and sterility. 2011;95(2):832-4. 
9) Davenport WB, Kutteh WH. Inherited Thrombophilias and Adverse Pregnancy 
Outcomes. A Review of Screening Patterns and Recommendations. Obstet 
Gynecol Clin N Amer. 2014;(41)133-144. 
10) Lockwood C, Wendel G, Silverman N. ACOG Practice Bulletin 138. Inherited 
Thrombophilias in Pregnancy. Obstet Gynecol 2013:122(3);706-16. 
11) Robinson L, Gallos ID, Conner SJ,  Rajkhowa M,  Miller D, Lewis S, Kirkman-
Brown J, Coomarasamy A. The effect of sperm DNA fragmentation on 
miscarriage rates: a systematic review and meta-analysis. Human Reproduction, 
Volume 27, Issue 10, 1 October 2012, Pages 2908–2917, 
https://doi.org/10.1093/humrep/des261 
12) Egerup P, Kolte AM, Larsen EC, Krog M, Nielsen HS, Christiansen OB. Recurrent 
pregnancy loss: what is the impact of consecutive versus non-consecutive 
losses? Hum Reprod 2016;31: 2428-2434. 
 
